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ABSTRACT 
“We may be born 100% human but will die 90% bacterial—a truly complex 
organism!” (Goodacre, 2007). This statement reflects the fact that there are 10 times 
more bacterial cells in the human body compared to the number of human cells, and 
there are 100 times more genes in the human microbiome compared to the number of 
genes in the human genome. Gut bacteria and host communicate with each other and 
collectively determine many aspects of host physiology such as bile acid (BA) and drug 
metabolism. Gut bacteria varies significantly between individuals and therefore, may be 
responsible for the inter-individual differences in BA concentrations and drug responses. 
There are a number of diseases such as obesity, inflammatory bowel disorder, and 
autism, that have been associated with an abnormal bloom in certain gut bacteria or a 
decrease in the diversity of gut bacteria. Therefore, modulating gut bacteria by 
probiotics, prebiotics, and by fecal transplantation have become viable therapeutic 
strategies. 
Alterations of gut bacteria in diseases or the therapeutic modulation of gut 
bacteria has the potential to alter host BA signaling and drug responses. Germ-free 
(GF) mice provide an excellent model system for understanding the functions of gut 
bacteria.  The overall goal of this dissertation is to expand the understanding of the role 
of gut bacteria in regulating host BA homeostasis and hepatic drug metabolism. 
In Specific Aim 1, I determined the changes in BA homeostasis and BA 
signaling in GF mice. BAs are amphipathic cholesterol metabolites that are synthesized 
in liver and secreted into bile. Gut bacteria metabolize primary BAs to secondary BAs. 
The majority of BAs is reabsorbed from the intestine, effluxed into the portal vein and 
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return to the liver. Therefore, the BA profile in the host is the result of the host hepatic 
enzyme activity and the gut bacterial enzyme activity. The BA profile is important 
because, BAs act like hormones and regulate host physiology by activating the BA 
receptors, namely the farnesoid X receptor (FXR) and transmembrane G-protein-
coupled receptor (TGR5).   
The BA profiles of both male and female GF mice are markedly altered 
compared to conventional (CV) mice. GF mice have an increase in total BAs in all the 
tissue compartments analyzed and decreased total fecal excretion of BAs compared to 
CV mice.  This could be due to slower intestinal propulsion rates and increased BA 
reabsorption from the intestines. The dominant BAs in GF mice are taurine conjugated α 
and β muricholic acids (Tα+β MCA). There is an increase in both ursodeoxycholic acid 
(UDCA) and MCAs and in the proportion of taurine conjugated BAs and these BAs 
result in a more hydrophilic BA pool in GF mice.  
UDCA which was previously considered to be a secondary BA that is 
synthesized by gut bacteria increases in GF mice. Biotransformation experiments in 
vitro demonstrated that UDCA can be synthesized from CDCA by enzymes present in 
hepatic microsomes isolated from both GF and CV mice. This explains why UDCA is 
increased in GF mice, and is evidence that UDCA is a primary BA synthesized by 
hepatic enzymes in mice. 
The altered BA profile in GF mice results in the activation of TGR5 signaling. 
Therefore, GF mice display all the characteristics of TGR5 activation, such as increased 
gallbladder size, increased serum GLP-1 levels, and increased mRNA of type 2 
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iodothyronine deiodinase (D2), the enzyme which increases energy expenditure as heat 
in brown adipose tissue. 
In Specific aim 2, I determined alterations in the mRNA of drug metabolizing 
enzymes in livers of GF mice by RNA-Seq.  Gene expression of a many hepatic Phase-
1 and Phase-2 enzymes was altered in the absence of gut bacteria.  Based on this 
study, I was able to generate of a list of genes in the liver that are altered by gut 
bacteria. Among these genes are Cyp2b10 and Cyp3a11 as their mRNAs were 
decreased in GF mice. In order to test the functional consequences, GF and CV mice 
were treated with the anesthetic pentobarbital and I observed that GF mice sleep longer 
than CV mice suggesting that pentobarbital metabolism is slower in GF mice. These 
observations strongly suggest that gut bacteria play an important role in regulating drug 
metabolizing enzymes in the liver. 
 Drug metabolizing enzymes with decreased mRNA levels in GF mice are 
probably increased in CV mice to help biotransform chemicals formed by gut bacteria. 
In contrast, drug metabolizing enzymes with increased mRNA levels in GF mice are 
likely enzymes whose function normally can be performed by the gut bacterial enzymes, 
and therefore in the absence of gut bacteria, are induced in the liver.  
In conclusion, this dissertation work has provided a detailed roadmap of 
alterations in BA composition, BA signaling, and expression of hepatic drug 
metabolizing enzymes in the absence of gut bacteria and will help to understand how to 
alter gut bacteria in a beneficial way. 
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1.1.1 Our microbial friends 
Human beings are merely an association of human and microbial cells and are 
thus called “supraorganisms” or “holobionts” (Backhed et al., 2004; Turnbaugh et al., 
2007; Gordon et al., 2013).  These microbes act as a “virtual organ”, and perform 
functions that benefit the host (O'Hara and Shanahan, 2006). There are many 
ecological habitats in the human body and each of these habitats allows for only a 
certain group of microbes to thrive. The microbial community size and composition vary 
between individuals and within an individual between the different body sites. The 
microbiota residing on each individual is unique and distinct just like an individual’s 
fingerprint. (Costello et al., 2009). Diet, environmental exposure, host genetics, and 
early microbial exposure are some of the factors that affect these microbial communities 
(Human Microbiome Project, 2012).  
Ever since the microscope was invented to study microbes, there has been an 
interest in learning about microbes that call the human body their home (Relman, 2009). 
Most of these organisms are anaerobic and therefore cannot be studied by traditional 
culturing methods (Salzman et al., 2002). Several new tools have been developed to 
study these microbes that have been difficult to culture, by using its genetic material. 
There is more microbial genetic material in the human body than human genetic 
material (Backhed et al., 2004; Turnbaugh et al., 2006; Turnbaugh et al., 2007). 
Metagenomics is the culture-independent study of the microbial DNA, RNA, and 
proteins to elucidate the structure and function of microbial communities in a sample 
(Gordon, 2012). These new tools help to find answers to questions such as, what is the 
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number of microorganisms present in the human body, what is their diversity and how 
do they influence the human body.  
One of the shocking revelations of the human genome project was that there are 
about 200 proteins encoded by the human genome that only have homologues in 
bacteria. This observation opened up the discussion about a possible horizontal transfer 
of these genes from bacteria to humans or even a possible gene transfer that occurs in 
the opposite direction, that is a horizontal transfer from vertebrates to bacteria (Lander 
et al., 2001). This observation resulted in a second human genome project to sequence 
the genetic material of all the endogenous microbiota (Relman and Falkow, 2001; 
Sears, 2005).  
The term ‘microbiome’ denotes the collective genome of all the indigenous 
microbes. There have been many projects initiated worldwide in the last decade to 
study the human microbiome. They include the Human Microbiome Project (HMP) of 
the US, the Metagenomics of the Human Gut Tract (MetaHIT) project of the European 
commission, the Canadian Microbiome Initiative and the Australian Jumpstart Human 
microbiome project.  These microbiome projects have provided a huge database with a 
wealth of information that has answered some questions and raised many more. 
Information from these studies have now demonstrated that among all other body 
sites, the intestinal tract has the largest number and biggest diversity of microbial 
species, and that bacteria constitute the major part of gut microbiota, however, viruses 
and yeast are also key residents (Group et al., 2009; Relman, 2012).  
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1.1.2  Establishment of gut bacteria 
The long standing belief is that human babies are born sterile and are later 
inoculated with the bacteria from the mother’s vagina if born vaginally or with the 
bacteria from the mother’s skin if born by caesarean section. However, recent studies 
illustrate the presence of bacteria in cord blood, fetal membranes, amniotic fluid, and 
baby’s first stool sample, questioning the dogma that the fetus is sterile (Jimenez et al., 
2005; Jimenez et al., 2008). Labelled gut bacteria administered to pregnant mice are 
detected in the gut contents of pups delivered by caesarean section, suggesting a 
vertical mother to baby transmission of gut bacteria (Jimenez et al., 2008). 
Breastfeeding is an additional route of transmission of maternal microbiota. Human 
breast milk has the appropriate nutrients to promote the growth of beneficial gut 
bacterial strains in the baby’s gut. In addition, breast milk also has anywhere between 
100 to 600 bacterial species, that populate the baby’s gut. Thus, by both the internal 
and external mother to baby transmission, the baby’s initial gut bacterial composition is 
shaped (Jimenez et al., 2008; Funkhouser and Bordenstein, 2013; Jost et al., 2013).   
The baby however, does not have a replica of the mother’s gut bacteria; instead 
babies have a signature gut bacterial composition that is very different from their 
parent’s gut bacteria (Palmer et al., 2007). Studies following changes in baby’s gut 
bacteria composition over time have illustrated that they are dynamic, but stabilize and 
resemble an adult’s gut bacteria composition by 3 years of age (Yatsunenko et al., 
2012). 
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1.1.3  Gut bacterial composition and number 
There are about 1014 microbial cells in the intestinal tract of human. This number 
is significant when one realizes that the whole human body has only about 1013 cells 
(Luckey, 1972). Sequencing the bacterial 16S rRNA gene has demonstrated that 
although there are significant inter-individual differences in the number of bacterial 
species, the gut bacteria are primarily composed of members belonging to the phyla 
Bacteroidetes and Firmicutes. Members of the phyla Proteobacteria, Actinobacteria, 
and Verrucomicrobia are also seen in the gut bacterial community but in smaller 
numbers (Eckburg et al., 2005). The ratio of the members of Firmicutes to Bacteroidetes 
is often quantified because of its association to increased energy extraction from food 
(Turnbaugh et al., 2006). Although the gut bacterial community composition of an 
individual displays some resilience, it can be perturbed by changes in age, diet and use 
of medications, such as antibiotics.  
Infant gut bacteria are dominated by the genus Bifidobacterium but its number 
decreases with age. More interestingly, a decreased number of Bifidobacterium in the 
gut of infants correlates with developing obesity in adults (Kalliomaki et al., 2008). The 
Firmicutes to Bacteroidetes ratio is low in infants and in elderly and high in adults 
(Mariat et al., 2009). Moreover, the diversity of the gut bacterial community decreases 
with age, which may lead to increased susceptibility to infections and decreased 
digestive capacity (Woodmansey, 2007). 
The gut bacterial community changes rapidly due to changes in the diet. Fat, 
carbohydrates, plant-based food that is high in fiber, and animal-based food that is high 
in amino acids are all factors that influence the bacterial population of the gut 
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(Turnbaugh et al., 2009; Faith et al., 2011).  Changing the diet from plant-based to an 
animal-based food for as little as four days modifies the gut bacteria from a predominant 
butyrate producing population to a predominant bile acid metabolizing population (David 
et al., 2014).   
The use of antibiotics can also alter the gut bacteria rapidly. After an antibiotic 
regimen, the gut bacterial community reverts back to its initial state in 3 weeks, 
although, the reversion process is incomplete and some bacterial species are lost in the 
process (Dethlefsen et al., 2008; Dethlefsen and Relman, 2011). Sub-therapeutic doses 
of oral antibiotics have been administered to farm animals to promote growth. Similarly, 
antibiotic use in humans is associated with obesity (Thuny et al., 2010). Recently, the 
growth promotion effects of oral sub-therapeutic antibiotics were demonstrated to be 
due to changes in gut bacteria (Cho et al., 2012). 
Dysbiosis or the imbalance in the proportion of beneficial and nonbeneficial 
bacteria in the gut is associated with a wide variety of human disorders, such as 
inflammatory bowel disorder (Frank et al., 2007), obesity (Ley et al., 2006) and autism 
(de Theije et al., 2013; Hsiao et al., 2013). Although, it is clear that the gut bacterial 
diversity is altered in these disorders, the question that still needs to be answered is 
whether this change in gut bacteria is the cause or effect of the disease. Furthermore, 
which group of the bacteria changes in disease states is controversial. For example, 
Ley et al. demonstrated that the proportion of Bacteroidetes ratio decreases and the 
proportion of Firmicutes to Bacteroidetes increases in the gut of obese individuals 
compared to lean individuals (Ley et al., 2006).  However, other studies contradict this 
observation (Duncan et al., 2008; Murphy et al., 2012) and associate obesity with an 
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increase in certain other groups such as Lactobacillus (Armougom et al., 2009; Million 
et al., 2011) and Staphylococcus (Kalliomaki et al., 2008). Another example, is the 
observation that there is a reduction in the members of the Firmicutes and 
Bacteroidetes phyla in the intestinal tract leading in some individuals with Crohn’s 
disease and ulcerative colitis (Frank et al., 2007). However, another study demonstrated 
an increase in members of the Bacteroidetes phyla (the genera Bacteroides and 
Prevotella) in inflammation-driven colon cancer (Sobhani et al., 2011; Ahn et al., 2013; 
Zackular et al., 2013). This emphasizes the fact that although the gut bacterial 
community is viewed as a pathogen, how gut bacteria may cause the disease in the 
host is often not clear. 
 
1.1.4 Benefits of gut bacteria 
The benefits of gut bacteria are multifold, ranging from extracting more energy 
from food to protecting against pathogens. Moreover, there is evidence to show that gut 
bacteria are important for host nutrition. Gut bacteria have enzymes to synthesize 
vitamins that the host cannot, especially vitamin K and vitamin B (LeBlanc et al., 2013). 
Gut bacteria also have enzymes to digest plant fibers and extract energy as short chain 
fatty acids (SCFAs), such as acetate, butyrate, and propionate from components of food 
that otherwise cannot be digested by the host (Backhed et al., 2004; Velagapudi et al., 
2010). Gut bacteria metabolize primary BAs to secondary BAs. In addition, gut microbes 
also influence the process of digestion by regulating the intraluminal levels of the 
neurotransmitters, such as norepinephrine, dopamine, and nitric oxide, thereby 
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regulating gut motility and gastric emptying (Sobko et al., 2005; Asano et al., 2012; 
Evans et al., 2013). 
Gut bacteria regulate intestinal immune and inflammatory responses. The 
communication between the gut bacteria-derived products and the toll-like receptors 
present on the intestinal epithelial cells and immune cells is important for protection 
against infection and inflammation (Rakoff-Nahoum et al., 2004; Arpaia et al., 2013; 
Furusawa et al., 2013). Incidentally, exposure to gut bacteria in early life is critical for 
this protection (Olszak et al., 2012). Gut bacteria also directly confer colonization 
resistance against pathogens by competing for food and production of acid and 
antibacterial peptides (Buffie and Pamer, 2013).   
The SCFAs that gut bacteria produce are also important for intestinal 
homeostasis (Rakoff-Nahoum et al., 2004). The majority of the SCFAs produced by gut 
bacteria is taken up by epithelial cells of the colon and is preferentially used by the 
colonocytes for energy. SCFA are anti-diarrheal as they promote sodium and water 
absorption (Scheppach, 1994). SCFAs also regulate the expression of tight cell junction 
proteins (Wang et al., 2012).  
Gut bacteria are seen as a therapeutic target because they can be altered by the 
administration of antibiotics, probiotics, and prebiotics or by fecal transplantation. 
Probiotics are defined as “live microorganisms, which when administered in adequate 
amounts confer health effect on the host” (Shen et al., 2013).  Prebiotics are “non-
digestible polysaccharides that promote SCFA production and the growth of beneficial 
gut bacteria, especially Bifidobacterium and Lactobacillus” (Shen et al., 2013).  
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Benefits of modulation of gut bacteria. Modulation of gut bacteria by antibiotics, 
probiotics, and prebiotics are being investigated as potential therapies for obesity and 
other diseases. For example, administration of the antibiotics norfloxacin and ampicillin 
alters gut bacteria and results in an improvement of glucose tolerance in various rodent 
models of obesity (Membrez et al., 2008). Treatment of high-fat diet fed mice with the 
probiotic VSL#3 (commercially available probiotic mixture of  Streptococcus 
thermophilus, three strains of Bifidobacterium and four strains of Lactobacillus) 
improved glucose tolerance (Ma et al., 2008). Treatment of mice on a high-fat diet with 
the prebiotic oligofructose, resulted in an increase in Bifidobacterium species in the gut 
and also improved glucose tolerance (Cani et al., 2007).   
Very few studies have been done in humans to test whether gut bacteria 
modulation can treat obesity. However, a recent human trial in the Netherlands 
demonstrated that transplanting fecal contents from lean donors to obese people 
resulted in improved glucose tolerance (Vrieze et al., 2012).  This observation takes the 
field one step forward, but a lot needs to be done with respect to identifying the bacterial 
group or the bacterial byproducts responsible for the therapeutic effect.  
 
1.1.5 Germ-free animals as tools to study gut bacteria  
In 1885, Louis Pasteur first proposed that to completely understand nutrition, 
experiments need to be performed on sterile GF animals. In 1896, Nuttal and 
Thierfelder generated the first GF animal, a GF guinea pig at the University of Berlin 
(Glimstedt, 1959; Wostmann, 1996). The following century witnessed a number of GF 
animal models being generated to study the function of gut bacteria. Almost half a 
century later, the first GF rats were generated by Gustafsson at the University of Lund 
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and by Reyniers at the Lobund laboratory at the University of Notre Dame (Gustafsson, 
1946; Reyniers et al., 1946; Gustafsson, 1948). Soon thereafter, Pleasants at the 
Lobund laboratory generated the first GF mice (C3H and Swiss Webster) by maintaining 
mouse pups born through cesarean section in a sterile chamber, and feeding the 
newborns a sterile milk formula (Pleasants, 1959).  At the present time, GF rats and 
mice are the preferred choice for research because of the relative ease in housing and 
handling.  
GF mice are ideally suited to study the function of gut bacteria and serve as a 
valuable research tool to unravel the role that gut bacteria play in normal physiology and 
pathology. More importantly, GF mice offer a model system that can be infected with the 
bacteria of choice to study the function of individual bacteria.  
However, as a consequence of having no gut bacteria, the anatomy and 
physiology of GF mice are altered to adapt to life with no microbial exposure. For 
example, in the gastrointestinal tract; there are many differences in the anatomy and 
physiology of GF and CV mice. Compared to CV mice, the GF mice have thinner small 
intestines with a reduced lamina propria and a reduced mucosal surface area, they 
have decreased number of lymphocytes and macrophages in the intestine, a reduced 
turnover rate of the intestinal epithelial cells, enlarged cecum, watery intestinal contents 
with a higher pH, slower gastric emptying, reduced intestinal motility, increased 
intestinal transit time, increased intestinal absorption of glucose (Abrams and Bishop, 
1967; Thompson and Trexler, 1971), and decreased vasculature (Stappenbeck et al., 
2002). All these changes need to be considered when interpreting the results obtained 
from GF mice. 
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1.1.6 Gut bacteria and BAs 
BAs made by the host modify gut bacterial composition and gut bacteria modify 
circulating BA composition in the host. BAs are one of the host factors that shape the 
gut bacterial community. Therefore, BA feeding has the potential to alter gut microbial 
composition (Islam et al., 2011). BAs act as hormones, binding to and activating the 
nuclear receptor FXR. FXR in turn regulates the immune system thereby indirectly 
regulating gut microbial composition (Devkota et al., 2012). 
Diets alter BA composition in bile and BAs alter gut bacterial composition. One 
view is that, the more animal fat in diet, the more BAs are secreted in bile to digest the 
fat, and these BAs result in the increase of BA-tolerant bacteria at the expense of other 
beneficial bacteria (Devkota et al., 2012).  For example, consuming a diet rich in milk fat 
increases taurine-conjugated CA and results in dysbiosis with an overgrowth of BA-
resistant bacteria such as Bilophila wardsworthia and development of colitis (Devkota et 
al., 2012). Further, these diet-induced changes in gut bacteria happen rapidly, in as little 
as four days (David et al., 2014).    
Gut bacteria have enzymes to metabolize BAs and change the BA composition in 
the intestinal content and also in the circulation of the host (Narushima et al., 2000; 
Narushima et al., 2006). The capacity to metabolize BAs not only provides gut bacteria 
cellular carbon, nitrogen and sulfur, but also enables them to be bile-resistant and grow 
in the presence of BAs. Gut bacteria perform the following modifications of BAs in the 
gut lumen:  deconjugation of taurine or glycine-conjugated BAs (by bile salt hydrolase), 
oxidation and epimerization of the 3-, 7- and 12-hydroxy groups of BAs (by 
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hydroxysteroid dehydrogenase) and 7-dehydroxylation (by 7-dehydratase). The 
enzymes bile salt hydrolase and hydroxysteroid dehydrogenase are present in a broad 
spectrum of gut bacteria, whereas enzymes for 7-dehydratase required to produce DCA 
and LCA are restricted to a small number of intestinal anaerobes such as Clostridium 
(Ridlon et al., 2006). 
The relationship between gut bacteria and BAs is important to understand 
because modifying gut bacteria can alter BAs and BA signaling, and similarly, altering 
BAs can modify gut bacteria and their secondary metabolites. Thus, they may be an 
effective therapeutic strategy to treat obesity (Li et al., 2013), inflammatory bowel 
disorder, (Trauner et al., 2013), and cancer (Yoshimoto et al., 2013). 
 
1.1.7 Gut bacteria and host drug metabolism 
Gut bacteria influence drug metabolism in the following ways (Morgan et al., 2008; 
Saad et al., 2012):  
1) They express enzymes that directly metabolize oral drugs and make drugs less 
or more active. 
2) They communicate with the immune system and regulate the expression of 
drug processing genes. 
3) Their metabolites regulate xenosensing transcription factors in the host and 
thus regulate expression of drug processing genes. 
4) Their metabolites compete with drugs for the same host drug metabolizing 
enzymes for clearance.  
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There are numerous examples of orally administered drugs being metabolized by 
gut bacteria. In fact, gut bacteria-mediated reduction of the azo bond is the basis of 
prodrugs such as sulfasalazine, which upon reduction in the colon gives rise to 5-
aminosalicylic acid (anti-inflammatory drug) and sufapyridine (antibiotic) (Sousa et al., 
2008; Stojancevic et al., 2013). Further, consumption of probiotics such as 
Bifidobacterium, Lactobacillus and Streptococcus can increase the gut bacteria-
mediated reduction of sulfasalazine (Lee et al., 2012).  
In addition to directly metabolizing orally administered drugs and changing their 
half-lives and the efficacy of these drugs, gut bacteria also influence the drug 
metabolizing capacity of the host. Endotoxin from the outer wall of gram-negative 
bacteria has the capacity to decrease the protein level and activity of major hepatic drug 
metabolizing enzymes (Ueyama et al., 2005). The antibiotic ciprofloxacin reduces LCA 
producing gut bacteria (Clostridium scindens, Clostridium sordelli, and Bacteroides 
fragilis) and decreases the expression of major drug metabolizing enzymes in the liver 
(Toda et al., 2009b; Toda et al., 2009a). 
Therefore, it is important to study the relationship between gut bacteria and host 
drug metabolism. Gut bacteria are unique for each individual and thus form another 
variable that determines how an individual will respond to a drug (Wilson, 2009). 
Metabolic byproducts of gut bacteria can be used to derive correlations to whether a 
person will metabolize the drug fast or slow in the gut and predict a person’s response 
to a drug (Kaddurah-Daouk et al., 2011). Thus, gut bacterial regulation of the drug 
metabolizing capacity of the host is certain to become an integral part of personalized 
medicine.  
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1.2. Bile acids (BAs) 
BAs are amphipathic detergent-like molecules that are synthesized in the liver, 
secreted in bile, stored in the gallbladder, and released into the duodenum after a meal. 
About 95% of BAs are absorbed across the intestine, by either passive diffusion or via 
transporters and are transported back to the liver via the portal circulation. This process 
is called the enterohepatic circulation. BAs are metabolized not only by the host 
enzymes but also by enzymes produced by bacteria in the intestine. Historically, BAs 
were thought to simply act as detergents, forming micelles and trapping lipids, and lipid 
soluble vitamins from the ingested meal, thereby aiding their absorption. However, BAs 
have proved to be more interesting with the discovery that BAs activate surface and 
nuclear receptors that regulate several cellular functions. In the last decade, it was 
discovered that BAs can regulate whole-body lipids and glucose metabolism through 
pathways regulated by the BA nuclear receptor, Farnesoid X receptor (FXR) 
(Makishima et al., 1999; Parks et al., 1999; Wang et al., 1999), and the BA cell 
membrane receptor, Transmembrane G protein-coupled receptor 5 (TGR5) (Maruyama 
et al., 2002; Kawamata et al., 2003). More recently, there is a growing understanding 
that individual BAs with different physico-chemical properties also have different binding 
affinities for the BA receptors and thus have different biological functions (Chiang, 
2009).  
1.2.1    Primary BA synthesis 
BAs are synthesized from cholesterol by enzymes in the liver that convert 
cholesterol to the primary BAs cholic acid (CA) and chenodeoxycholic acid (CDCA) in 
humans, and also to muricholic acid (MCA) in mice. The reactions involved include:  
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1) Saturation of the double bond (between 5th and 6th position) (Fig 1A) 
2) Epimerization of the 3β-OH group 
3) Introduction of OH groups at the 6, 7 and 12 positions 
4) Oxidation and shortening of the side chain (C27 to C24) 
5) Conjugating the carboxylic group in the side chain with a taurine or glycine 
moiety.  
The conversion of cholesterol to BAs reflects the high capacity of the liver to convert 
a lipid-soluble substance to a more water-soluble product that can be secreted into bile. 
Cholesterol has a solubility of approximately 10 nM in water (Renshaw et al., 1983), 
whereas primary BAs have a solubility of approximately 1.3 M (Small et al., 1966; Shea 
et al., 2007). Although the type of reactions involved in the formation of BAs are similar 
to those involved in drug metabolism, namely hydroxylation, oxidation, and conjugation, 
some reactions in BA synthesis are highly specific and regulated (Staple and Gurin, 
1954). The steps involved in the synthesis of primary BAs are shown in Figure 1B. The 
exact order of steps remains unclear because many of the intermediates serve as 
substrates for more than one biosynthetic enzyme (Russell, 2003). The synthesis of 
primary BAs is initiated by either the classic or the alternative pathway till the branch 
point intermediate is synthesized, which then undergoes a series of enzymatic reactions 
to be converted to the various primary BAs (Fig 1B). 
Classic Pathway  
In the classic pathway of BA synthesis, the first step is the conversion of 
cholesterol to 7α-hydroxycholesterol by the microsomal cytochrome P450 enzyme (Cyp) 
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cholesterol 7α-hydroxylase (Cyp7a1) that is expressed only in liver. Cyp7a1 is the rate-
determining enzyme in BA synthesis and expression of Cyp7a1 is highly regulated.  
Alternative Pathway 
The first step in the alternative pathway is the conversion of cholesterol to either 
27-hydroxycholesterol by the enzyme sterol 27-hydroxylase, a mitochondrial 
cytochrome P450 enzyme (this enzyme can also make 24- and 25-hydroxycholesterol) 
or 24-hydroxycholesterol by the enzyme oxysterol 24-hydroxylase, a microsomal 
cytochrome P450 enzyme that is expressed largely in the brain and at much lower 
levels in the liver (Russell, 2003).  
The second step is the 7α-hydroxylation of the oxysterols. Microsomal enzyme 
Cyp7b1 performs 7α-hydroxylation of either 27-hydroxycholesterol or 25-
hydroxycholesterol and another microsomal enzyme, Cyp39a1 performs 7α-
hydroxylation of 24-hydroxycholesterol. In mice, about 25-30% of BAs are thought to 
originate through the alternative pathway whereas in humans only about 5-10% of BAs 
are thought to be from the alternative pathway (Russell, 2003). 
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Fig.1.1.  A) Conversion of cholesterol to Cholic acid  B) General scheme of primary bile 
acid synthesis from cholesterol in the liver ,* denotes responsible enzyme is not yet  identified. 
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Other steps in primary BA synthesis 
The other ring hydroxylations that occur during the synthesis of primary BAs 
include 7-epimerization (to convert 7α-OH to 7β-OH) and 6β-hydroxylation. However, 
the enzymes that are responsible for these reactions are still unknown. The 7-
hydroxylated intermediates derived from cholesterol are substrates for the enzyme 3β 
hydroxysteroid dehydrogenase 7 (HSD3β7), which isomerizes the double bond from the 
5th to the 4th carbon and oxidizes the 3β-hydroxyl group to a 3-keto group (Russell, 
2003).  
The products of the HSD3β7 enzyme can have two fates. If acted upon by the 
microsomal enzyme Cyp8b1 the resulting product will have a 12-OH group and will 
ultimately be converted to CA. In the absence of 12-hydroxylation, the intermediate will 
ultimately be converted to CDCA (rat, mouse, human), α- and β- MCA acid (mouse), 
and ursodeoxycholic acid (UDCA) (bear). The subsequent enzymes in the cascade are 
cytosolic aldo-keto reductase 1c4 (AKR1c4) and AKR1d1 that reduce the 3-keto group 
to an alcohol and reduce the double bond between the 4th and the 5th carbon.  
The last step in the primary BA synthesis involves side chain oxidation performed 
by the enzyme Cyp27a1 and side chain shortening or removal of the terminal three 
carbon atoms in the peroxisomes by a series of reactions that are similar to β-oxidation 
of fatty acids. The enzymes involved in the side chain shortening are BA CoA ligase, 2-
methylacyl-CoA racemase, branched-chain acyl-coenzyme A oxidase 2 (ACOX2), D-
bifunctional protein, and peroxisomal thiolase 2 (Russell, 2003).  
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Bile acids Abbrev. 3α 3β 6α 6β 7α 7β 12α 12β
Primary bile acids
cholic acid CA OH H H H OH H OH H
chenodeoxycholic acid CDCA OH H H H OH H H H
α-muricholic acid αMCA OH H H OH OH H H H
β-muricholic acid βMCA OH H H OH H OH H H
7-Dehydroxylation products
deoxycholic acid DCA OH H H H H H OH H
lithocholic acid LCA OH H H H H H H H
murideoxycholic acid MDCA OH H H OH H H H H
Oxidation products
3-dehydro-cholic acid 3-DehydroCA H H OH H OH H
7-oxo-deoxycholic acid 7-OxoDCA OH H H H OH H
12-oxo-chenodeoxycholic acid 12-OxoCDCA OH H H H OH H
3-dehydro-deoxycholic acid 3-DehydroDCA H H H H OH H
12-oxo-lithocholic acid 12-OxoLCA OH H H H H H
3-dehydro-chenodeoxycholic acid 3-DehydroCDCA H H OH H H H
7-oxo-lithocholic acid 7-OxoLCA OH H H H H H
dehydro-lithocholic acid DehydroLCA H H H H H H
6-oxo-lithocholic acid 6-OxoLCA OH H H H H H
6-oxo-ursodeoxycholic acid 6-OxoUDCA OH H H OH H H
Reduction/Epimerization products
iso-cholic acid IsoCA H OH H H OH H OH H
ursocholic acid UCA OH H H H H OH OH H
12-epi-cholic acid 12-EpiCA OH H H H OH H H OH
iso-deoxycholic acid IsoDCA H OH H H H H OH H
12-epi-deoxycholic acid 12-EpiDCA OH H H H H H H OH
iso-chenodeoxycholic acid IsoCDCA H OH H H OH H H H
ursodeoxycholic acid UDCA OH H H H H OH H H
iso-lithocholic acid IsoLCA H OH H H H H H H
hyodeoxycholic acid HDCA OH H OH H H H H H
ω-muricholic acid ωMCA OH H OH H H OH H H
=O
=O
=O
=O
=O
=O
=O
=O
=O
=O
 
 
 
Table 1.1 Bile acid nomenclatures and structures (adapted from Zhang et al, 2011) 
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BA Conjugation 
In mice, BAs are mainly conjugated with taurine, and in humans with glycine and 
taurine by an amide linkage to C-24. The liver has a high capacity for conjugation and 
therefore more than 98% of BAs excreted from the liver are conjugated (Russell, 2003). 
Conjugation lowers the pKa of BAs, enhancing aqueous solubility at the pH of the 
proximal intestine, and promotes a high intraluminal BA concentration leading to 
efficient solubilization of lipids and fat-soluble vitamins. Two enzymes catalyze the 
reactions leading to bile acid amidation. A CoA thioester is first formed by the rate-
limiting BA-CoA ligase (BAL) enzyme and then glycine or taurine is coupled to the 
carboxyl group of the BA in a reaction catalyzed by cytosolic BA-CoA:amino acid N-
acyltransferase (BAAT) (Setchell et al., 2013).  
When the conjugated primary BAs reach the intestine via bile, the gut bacteria 
deconjugate the conjugated primary BAs and then metabolize them to secondary BAs 
(Ridlon et al., 2006) (Fig. 1.2). Most of these BAs enter the enterohepatic circulation 
where they are transported across the intestine and then reenter the liver. The BAL 
enzyme in the liver efficiently re-conjugates both the primary and secondary BAs 
(Hubbard et al., 2006). 
Enzymes important for BA synthesis 
Cyp7a1: It is the first enzyme, and the rate determining enzyme, in the classic 
pathway of BA synthesis. Mutations in the CYP7A1 gene in humans result in a 
metabolic disorder with increased whole-body cholesterol, increased plasma 
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triglycerides, and cholesterol gallstones. Fecal BA excretion is 6% of normal, with higher 
CDCA compared to CA levels, increased CYP27A1 activity, and an induction in the 
alternate pathway of BA synthesis (Pullinger et al., 2002).  
Cyp7a1-null mice have an increased rate of postnatal death. Most pups die 
within the first 18 days, unless the mothers are supplemented with CA and vitamins 
(Ishibashi et al., 1996). The enzyme Cyp7b1 (oxysterol 7α-hydroxylase) of the alternate 
pathway of BA synthesis is induced between the third and fourth week of life and the 
alternate pathway takes over BA synthesis in mice that are deficient in the enzyme. 
Serum cholesterol and triglycerides are similar, whereas vitamin D and E levels are 
lower in Cyp7a1-null mice (Schwarz et al., 1996). The BA pool size and BA synthesis 
rate measured as excretion of BAs in feces are both reduced by more than 50% in 
mice, when Cyp7a1 is absent (Schwarz et al., 2001).  
In Cyp7a1-null mice cholesterol feeding and cholestyramine feeding do not affect 
the rate of BA synthesis, which is mostly through the alternate pathway in these null 
mice (Schwarz et al., 2001). This indicates that the alternate pathway of BA synthesis is 
not inducible by changes in enterohepatic circulation of BAs in contrast to the classic 
pathway.  The BA composition in bile and feces are very different in Cyp7a1-null mice 
compared to controls, with the concentration of CA being decreased more than 50% 
(Schwarz et al., 1996). The reduced proportion of CA in bile and subsequently in the 
intestine results in reduced absorption of vitamins D and E and cholesterol across the 
intestine in Cyp7a1-null mice, and feeding CA restores their uptake (Schwarz et al., 
1998). This indicates that the proportion of CA is important for the uptake of cholesterol 
and fat soluble vitamins across the intestine.    
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Cyp27a1: The sterol 27-hydroxylase enzyme or Cyp27a1 is a mitochondrial 
enzyme that plays two important roles in BA synthesis:  
1) it is responsible for the first step in the steroid side chain cleavage to convert  
C27 cholesterol or its metabolites to C24 BAs.  
2) it is responsible for the first step in the alternate pathway of BA synthesis by 
generating oxysterols (25- and 27-hydroxycholesterol) from cholesterol.   
Deficiency of the enzyme CYP27A1 in humans leads to an autosomal recessive 
disease called cerebrotendinuos xanthomatosis, a rare sterol storage disease, 
characterized by progressive neurological dysfunction and premature artherosclerosis.  
(Cali et al., 1991). CDCA treatment lowers plasma cholesterol levels and decreases 
accumulation of abnormal BAs by repressing the activity of CYP7A1 via FXR (Honda et 
al., 2001). 
Cyp27-null mice have markedly lower BA synthesis even though Cyp7a1 activity 
is increased 5-fold. BA synthesis was measured by the conversion of injected 
radiolabeled 7α-hydroxycholesterol into BAs in bile (Rosen et al., 1998). Cyp27-null 
mice have a decreased BA pool size, increased proportion of CA, decreased fecal BA 
excretion, decreased feedback regulation by FXR and decreased intestinal cholesterol 
absorption. There is however, a compensatory increase in hepatic cholesterol and fatty 
acid synthesis. Feeding CA to Cyp27-null mice restores normal intestinal absorption of 
cholesterol and normal hepatic cholesterol, and fatty acid synthesis (Repa et al., 2000). 
Cyp27-null mice do not develop the disease cerebrotendinuos xanthomatosis, because 
unlike humans, Cyp27-null mice have a microsomal 25-hydroxylation side-chain 
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cleavage pathway and Cyp7a1 activity is not upregulated as much as in the 
cerebrotendinuos xanthomatosis patients (Honda et al., 2001). 
Cyp7b1: Oxysterol 7α-hydroxylase or Cyp7b1 was identified as the 7α-
hydroxylase that is upregulated after 21 days of age in mice. This enzyme is part of the 
alternate pathway of BA synthesis and its expression is sexually dimorphic being 3-fold 
higher in male than in female mice (Schwarz et al., 2001).  
Defects in the CYP7B1 gene in humans result in severe neonatal cholestasis. 
The defect in the gene results in the accumulation of high concentrations of hepatotoxic 
monohydroxy BAs with the 3β-hydroxy-Δ5 structure and a drastic reduction in normal 
primary BAs that provide the driving force for bile flow. This is a rare autosomal 
recessive condition and was fatal in the two infants diagnosed with this defect (Setchell 
et al., 1998; Ueki et al., 2008).  CYP7A1 activity is not detected in livers of infants below 
one year of age, demonstrating the importance of the enzyme CYP7B1 and the 
importance of the alternate pathway of BA synthesis in neonates and infants 
(Gustafsson, 1986; Setchell et al., 1998). The ontogeny of Cyp7a1 and Cyp7b1 in mice 
and humans seem to be opposite; in mice Cyp7a1 is expressed at birth and Cyp7b1 
develops after the third week of age, whereas in humans CYP7B1 is expressed at birth 
and CYP7A1 develops after 1-2 years of age.  
Deficiency of Cyp7b1 in mice results in a much less significant phenotype 
compared to humans, as loss of Cyp7b1 in mice is compensated for by an increase in 
the synthesis of BAs by other pathways. There is a 30% increase in Cyp7a1 protein in 
livers of Cyp7b1-null mice which may result in a 30% increase in the output of BAs from 
the classic pathway of BA synthesis. The BA pool size, BA composition, intestinal 
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absorption of cholesterol, serum cholesterol, and serum triglyceride levels were similar 
in Cyp7b1-null mice and wild-type controls (Li-Hawkins et al., 2000). 
Cyp8b1: Sterol 12α-hydroxylase or Cyp8b1 is a microsomal enzyme that 
hydroxylates C-12 of cholesterol metabolites to form CA. Deletion of the Cyp8b1 gene 
in mice prevents the synthesis of CA and DCA. The BA synthesis and pool size 
increase in Cyp8b1-null mice, and the BA composition is altered with a decrease in CA 
and a compensatory increase in the proportion of α and β MCA. There is a decrease in 
small heterodimer partner (SHP) mRNA and protein and a corresponding increase in 
Cyp7a1 protein and activity (Li-Hawkins et al., 2002). In Cyp8b1-null mice which have a 
lower proportion of CA, cholesterol absorption across the intestine is less and feeding 
CA to these mice reverses this situation, indicating that CA is an important determinant 
of cholesterol uptake across the intestine (Li-Hawkins et al., 2002; Murphy et al., 2005). 
AKRs: Two AKR (Aldo-keto reductase) enzymes, Δ4-3-oxosteroid,5β-reductase 
(Akr1d1) and 3α-hydroxysteroid dehydrogenase (Akr1c4) catalyze the reduction of the 
double bond at C-4 and the reduction of the 3-keto group to an alcohol in the stereo-
chemical alpha configuration, respectively. 
Akr1d1 deficiency in humans leads to neonatal hepatitis and cholestasis. The 
patients with Akr1d1 deficiency are characterized by decreased primary BA synthesis 
and accumulation of hepatotoxic Δ4-3-oxo and 5α-reduced BAs. This deficiency is 
treated with primary BAs, which normalize liver morphology and function (Drury et al., 
2010). 
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Bile acid-CoA Ligase (BAL): BAL is the enzyme that catalyzes the addition of 
CoA to BAs that will be conjugated with the amino acids taurine or glycine by the 
enzyme BA-CoA: amino acid N-acyltransferase (BAAT) before secretion into bile. Liver 
has a high capacity for conjugation, and less than 2% of BAs are unconjugated in bile 
under normal conditions (Matoba et al., 1986; Setchell et al., 2013). 
BAL-null mice have normal BA pool size and normal BA concentrations in liver, 
serum, gallbladder bile, and urine compared to controls. The majority of the BAs are 
unconjugated in mice with BAL deficiency unlike normal mice in which the majority of 
the BAs are conjugated with taurine. BAL-null mice also have a small proportion of 
primary (less than 5% of BAs) but no secondary BAs that are conjugated and these BAs 
are most likely synthesized de novo. This suggests that there is a specific requirement 
for BAL enzyme in reconjugation of BAs during enterohepatic circulation (Hubbard et 
al., 2006). 
Bile acid-CoA:amino acid N-acyltransferase (BAAT): Conjugation of BAs with 
taurine or glycine lowers the pKa of the BA, increasing aqueous solubility, and promotes 
a high intraluminal BA concentration, and thus, efficient solubilization of lipids with low 
aqueous solubility, such as saturated fats and fat-soluble vitamins. A genetic defect in 
BAAT in humans disrupts BA conjugation and causes fat-soluble vitamin deficiency and 
growth failure, demonstrating the importance of BA conjugation in lipid absorption. In 
addition, unconjugated BAs are not well transported by canalicular BA transporters and 
may accumulate in hepatocytes causing injury in some patients (Setchell et al., 2013). 
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1.2.2   Secondary BA synthesis 
When BAs pass through the intestine they encounter a low number and low 
diversity of facultative and anaerobic bacteria in the small intestine, where the major BA 
metabolism is deconjugation and hydroxyl group oxidation. 7α-Dehydroxylation of the 
primary BAs, CA and CDCA  produce the secondary BAs, DCA and LCA, respectively, 
are largely the action of bacteria that are present in the large intestine (Ridlon et al., 
2006).  
A) Deconjugation of BAs: Deconjugation involves the enzymatic hydrolysis of the 
N-acyl amide bond linking BAs (24-C) to taurine or glycine. The enzyme 
responsible is called bile salt hydrolase (BSH) and has been isolated from 
several species of gut bacteria. Glycine and taurine can serve as substrates for 
microbial metabolism. Thus, deconjugation may be a means of obtaining cellular 
carbon, nitrogen, and sulfur for some gut bacteria. Taurine contains a sulfonic 
moiety that is reduced and dissimilated to hydrogen sulfide after deconjugation. 
Hydrogen sulfide is highly toxic and has been implicated in the pathogenesis of 
colon cancer. Moreover, hydrogen sulfide inhibits butyrate metabolism in 
colonocytes, which is a key nutrient and regulator of cell turnover in the gut 
(Ridlon et al., 2006). 
B) Oxidation and epimerization of BAs:  Epimerization of the hydroxyl groups in 
BAs is performed by specific gut bacterial hydroxysteroid dehydrogenase 
(HSDH) enzymes. The gut bacteria use the reducing equivalents generated 
during the oxidation of hydroxyl groups in BAs (Ridlon et al., 2006). 3α- and 3β-
HSDHs catalyze the reversible, stereospecific oxidation/reduction reaction 
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between 3-keto-BAs and 3α- or 3β-hydroxy BAs. This enzyme is found in 
members of the species Clostridium and Rumminococcus (Ridlon et al., 2006).  
 The 7α- and 7β-HSDHs catalyze the reversible stereospecific 
oxidation/reduction reaction of the 7α and 7β-hydroxyl groups of BAs.  This 
enzyme is seen in bacteroides and Clostridia, as well as in E. Coli and 
Ruminococcus species (Ridlon et al., 2006). 
The 12α- and 12β-HSDHs are responsible for the reversible 
oxidation/reduction reaction of the 12α-hydroxyl group of BAs. This enzyme is 
detected mainly in the members of the genus Clostridium (Ridlon et al., 2006). 
C) 7-Dehydroxylation of BAs: Conjugated primary BAs are the most abundant 
BAs seen in bile and unconjugated secondary BAs are the most abundant BAs 
seen in feces. Therefore, the 7α-dehydroxylation reaction, which forms 
secondary BAs from primary BAs, is quantitatively the most important bacterial 
BA biotransformation.  It can occur only after deconjugation of the taurine or 
glycine moiety from the BA and is a multi-step pathway that requires multiple bile 
acid inducible (bai) genes that are often organized as an operon in bacteria. 
Human gut bacteria capable of BA 7α-dehydroxylation have been isolated from 
the colon and classified to the genus Clostridium (Wells et al., 2003). The ability 
to generate secondary BAs by these bacteria must confer a growth advantage to 
these bacteria compared to bacteria that cannot metabolize BAs (Ridlon et al., 
2006). 
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1.2.3    Enterohepatic circulation of BAs 
Bile originates in the liver and serves as an excretory fluid and aids digestion. 
Bile contains BAs, bilirubin, glutathione conjugates, cholesterol, phospholipids-mainly 
phosphatidylcholine (PC), proteins, electrolytes, such as sodium, potassium, chloride, 
and bicarbonate, and metabolites of lipophilic xenobiotics or heavy metal cations that 
the body is trying to eliminate (Klaassen and Watkins, 1984). 
The concept of a biliary cycle dates back to the 17th century. Mauritius Van 
Reverhorst, stated that a large volume of bile flow can occur daily, only if bile re-
circulates, similar to William Harvey’s description of blood flow. Van Reverhorst 
calculated that the amount of bile entering the duodenum is greater than the amount 
that is excreted (Reuben, 2005). Therefore, he suggested a “motus bilis circularis or an 
enterohepatic circulation of bile, meaning bile is continuously excreted and reabsorbed” 
(Van Reverhorst, 1696; Reuben, 2005).  
Giovanni Alfonso Borelli explained enterohepatic circulation as we understand it 
today: bile is made in the liver, flows into the duodenum after a meal and is mixed with 
the food in the intestine, then most of it passes through the intestine wall to enter the 
portal vein to be carried back to the liver, and a small amount of bile is eliminated in 
feces (Reuben, 2005). 
Moritz Schiff demonstrated that the daily bile salt secretion rate in bile is 
increased if bile is returned to the intestine instead of being excreted. (Verkade et al., 
1995; Reuben, 2005). BAs are the component of bile that is responsible for the 
stimulation of bile flow  (Foster et al., 1919; Whipple and Smith, 1928). This choleretic 
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responses to BAs is different in various species, and this is due to differences in basal 
bile production (Klaassen, 1972). The bile flow that originates from the osmotic action of 
BAs is termed BA-dependent bile flow. 
Treatment of rats with phenobarbital for 4 days increased bile formation by 50%.  
Biliary clearance of 14C-labeled erythritol illustrated that the bile was of hepatocyte origin 
in both the control and treated rats. However, the concentration of BAs in the treated 
rats were lower than control and they decreased with time (Klaassen, 1969; Berthelot et 
al., 1970; Klaassen, 1971). So this portion of the bile flow is not due to the osmotic 
action of BA and is called BA-independent bile flow. The primary osmotic driving force 
responsible for the BA-independent bile flow is glutathione (Ballatori and Truong, 1992), 
which is pumped across the apical membrane of the hepatocytes by the transporter 
Mrp2 (Johnson et al., 2002). 
Bile flow begins in the liver. The movement of BAs in the enterohepatic 
circulation begins in the centrolobular hepatocytes where BAs are formed de novo and 
conjugated with taurine or glycine (Hofmann, 1999). Transporters present on the apical 
membrane of hepatocytes, such as the bile salt export pump (Bsep), with the help of 
ATP, transport BAs against the concentration gradient into bile canaliculi (Green et al., 
2000). The heterodimeric transporter Abcg5/Abcg8 transports cholesterol and plant 
sterols into the bile canaliculus (Berge et al., 2000; Repa et al., 2002). The canaliculus 
is surrounded by a spiral ribbon of actin filaments. The osmotic gradient generated by 
the actively pumped BAs, pulls water and other solutes into the canaliculus, which is 
then squeezed by the surrounding actin filaments.  
31 
 
BAs then adsorb to the phosphatidyl choline (PC) molecules on the luminal side 
of the canalicular membrane, and detach the PC molecules on the outer leaflet of the 
canalicular membrane which are then replaced by the PC floppase Mdr2 (MDR3 in 
humans). Initially, BAs and PC molecules form vesicles, but when the concentrations of 
BAs increase, the vesicles fuse to form mixed micelles (Verkade et al., 1995; Hofmann, 
1999). The canaliculi empty via the canals of Hering and flow into the biliary tract and 
reach the gallbladder. After a meal, release of cholecystokinin from the endocrine cells 
of the intestine causes gallbladder contraction and relaxation of the sphincter of Oddi, 
causing bile to flow into the intestine (Hofmann, 1999). 
Actions of the hepatic BA transporters ensure normal bile flow. Inhibition of PC 
biosynthesis by feeding a choline-deficient diet or anti-microtubule drugs such as 
colchicine, lead to inhibition of the biliary phospholipid and cholesterol secretion without 
affecting that of BAs (Verkade et al., 1995).  
BAs flow through the intestine where they are reabsorbed. BAs in mixed 
micelles flow through the intestinal lumen. In the small intestine, BAs being detergent-
like promote the solubilization of fatty acids from the diet in mixed micelles, and help 
them diffuse through the unstirred layer along the intestine wall, increasing lipid 
absorption (Hofmann, 1999).  
Conjugated BAs have a lower pKa and thus are ionized at the pH of the small 
intestine. So the intraluminal BA concentration is high, being toxic to gut bacteria 
(Ridlon et al., 2006). The gut bacteria in defense deconjugate the conjugated BAs and 
then 7-dehydroxylate them to make secondary BAs, which are more lipid-soluble. The 
32 
 
terminal ileum is the site where most BAs are actively transported from the gut lumen 
into the enterocyte by the apical sodium dependent transporter (Asbt) (Wong et al., 
1994). The unconjugated BAs are absorbed by passive absorption across the distal 
small intestine and large intestine. BAs are transported from inside the enterocyte to the 
portal vein by the basolateral organic solute transporter α and β (Ost α and Ost β) 
(Dawson et al., 2005). Less than 5% of BAs are excreted in feces. The fecal loss is 
replaced by en equal daily de novo synthesis of BAs by the liver to maintain the BA pool 
size. 
BAs return to the liver. BAs are carried from the intestine to the liver by the 
portal vein, mostly bound to albumin. Periportal hepatocytes efficiently extract the BAs 
from blood. Most conjugated BAs are thought to be transported into the hepatocytes by 
the sodium taurocholate cotransporting polypeptide (NTCP) (Hagenbuch et al., 1991) 
and unconjugated BAs are transported by the organic anion-transporting polypeptide 
1b2 (Oatp1b2) (Csanaky et al., 2011). 
  Secondary BAs that reach the liver from the intestine are conjugated with taurine 
or glycine, and at times, even sulfated (especially LCA). If the secondary BAs are 
conjugated with taurine or glycine and sulfated, they are not efficiently reabsorbed by 
the intestine and are eliminated in feces. Unconjugated primary BAs returning from the 
intestine are also re-conjugated in the liver with taurine or glycine, and these BAs 
reenter the bile completing the enterohepatic circulation. 
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1.2.4   BA transporters 
Enterohepatic circulation of BAs is mediated by the action of specific 
transporters. Transporters are specialized membrane proteins with extracellular, 
transmembrane and cytoplasmic domains, which transport hydrophilic solutes across 
the lipid bilayer of the cell membrane. Transport of BAs is carried out by members of 
two superfamilies of transporters: 1) ATP-binding cassette transporters (ABC 
transporters) and 2) Solute carrier transporters (Slc transporters).  
Note: Homologous transporters in humans and mice having the same name are 
differentiated by referring to the human transporters in all capitalized letters and the 
mouse transporters have only the first letter capitalized. 
 BA Transporters in hepatocytes 
The basolateral membranes of hepatocytes have both uptake and efflux BA 
transporters. The BA uptake transporters on the basolateral surface of the hepatocytes 
extract BAs from the hepatic sinusoids. The efflux transporters on the basolateral 
membrane pump excess BAs out of hepatocytes into blood, which would be 
subsequently taken in by downstream hepatocytes to facilitate a process called 
“hepatocyte hopping” to prevent the periportal hepatocytes from being saturated with 
BAs (van de Steeg et al., 2010). Basolateral BA uptake transporters include Ntcp and 
Oatp1b2 and basolateral BA efflux transporters include Mrp3, Mrp4, and Ostα-Ostβ. 
The BA concentrations within the hepatocytes are presumed to be in the micromolar 
range and the canalicular BA concentrations are about 1000-fold higher, therefore 
necessitating active transport across the apical membrane (Dawson et al., 2009). The 
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apical BA efflux transporters include Bsep and Mrp2, which transport BAs into bile 
canaliculi. No apical BA uptake transporter has been identified on hepatocytes. 
A. Sodium taurocholate cotransporting polypeptide (Ntcp): The transporter 
Ntcp (Slc10a1) is present on the basolateral membrane of hepatocytes (Stieger 
et al., 1994; Aleksunes et al., 2006) and is thought to be responsible for the 
sodium-dependent uptake of conjugated BAs in a sodium-dependent manner 
from portal blood. Ntcp was first cloned from rat liver (Hagenbuch et al., 1991). 
  Currently no human diseases are known that are caused by mutations in 
the SlC10A1 gene (Shneider et al., 1997; Carlton et al., 2003; Stieger, 2011). 
This could be either because NTCP expression is so important that its absence 
would lead to early death, or there is another transporter that mediates hepatic 
uptake of BAs. However, down regulation of the SLC10A1 gene and protein 
expression are seen in several pathophysiological conditions, such as 
progressive obstructive cholestasis due to biliary atresia (Shneider et al., 1997). 
Animal models of cholestasis, such as bile-duct ligation also lead to a 
decrease in the expression of the Slc10a1 gene, probably to prevent the liver 
from accumulating toxic BAs (Donner et al., 2007; Slitt et al., 2007). Ntcp shows 
gender divergent expression in mice. Female mice have higher Ntcp protein and 
mRNA levels in liver, and this is due to the inhibitory effect of male-pattern 
growth hormone secretion (Cheng et al., 2007). BA homeostasis in Ntcp-null 
mice has not yet been characterized.  
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B. Organic anion transporting polypeptides (Oatps): The transporters OATP1B1 
and OATP1B3 in humans and its homolog in rodents Oatp1b2 (Slco1b2) are 
located on the basolateral membrane of hepatocytes and play an important role 
in the sodium-independent uptake of endogenous substrates, such as BAs into 
hepatocytes (Jacquemin et al., 1994). These Oatps were isolated exclusively in 
human and rodent liver and so was previously termed liver-specific organic anion 
transporter (LST-1/Lst-1) (Abe et al., 1999).  Humans with low-activity OATP1B1 
polymorphisms have higher serum BAs, indicating that OATP1B1 plays an 
important role in the hepatic uptake of BAs in humans (Xiang et al., 2009). 
OATP1B3 may play a role in the hepatic uptake of BAs in humans, but 
polymorphisms in the SlCO1B3 gene have not been reported. 
Oatp1b2-null mice have 3- to 45-fold higher unconjugated BAs in serum. 
They also have decreased clearance of intravenously injected CA but not TCA. 
This demonstrates that Oatp1b2 in mice is important for the basolateral uptake of 
unconjugated BAs (Csanaky et al., 2011). 
C. Multidrug resistance-associated proteins (Mrps): Several members of the 
Mrp family are expressed in hepatocytes. Mrp2 (Abcc2) is important for BA 
transport. Mrp2 is present on the canalicular (apical) membrane of hepatocytes 
(Scheffer et al., 2000) and is responsible for the efflux of sulfated and/or 
glucuronidated BAs. Mrp2 is a major determinant of BA-independent bile flow by 
transporting glutathione.  
Human MRP2 can transport UDCA and TUDCA when expressed in Sf9 
cell membranes (Gerk et al., 2007). Mutations in the MRP2 transporter in 
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humans are linked to the Dubin-Johnson syndrome, characterized by reduced 
efflux of conjugated bilirubin into bile (Kartenbeck et al., 1996; Paulusma et al., 
1997).  
Mrp2-null mice exhibit biochemical abnormalities that are similar to those 
described in Dubin-Johnson syndrome patients, such as increased serum and 
urine bilirubin glucuronide, increased hepatic glutathione concentrations, and 
reduced bile flow rate (Chu et al., 2006; Kruh et al., 2007). 
D. Bile salt export pump (Bsep): The transporter Bsep (Abcb11), which was 
originally called “sister” of P-glycoprotein, is localized on the apical or canalicular 
membrane of hepatocytes (Childs et al., 1998; Jansen et al., 1999; Green et al., 
2000) and functions to efflux conjugated BAs from hepatocytes into bile. Bsep 
was first identified in a pig liver cDNA screening (Childs et al., 1995) and  in a rat 
hepatoma cell line that was resistant to the methyl ester of glycocholic acid 
(Brown et al., 1995). The full-length cDNA of Bsep was cloned from rat liver 
(Gerloff et al., 1998). Humans with mutations in BSEP that lead to the absence of 
BSEP function develop progressive familial intrahepatic cholestasis type 2 
(PFIC2), which often progresses to hepatic failure. Total BA secretion in these 
patients is only 1% of normal (Jansen et al., 1999), with a decrease in synthesis 
of both CA and CDCA. Administration of UDCA helps to improve the liver 
function of some of these patients (Takahashi et al., 2007). This demonstrates 
that there is no backup in humans for BSEP’s function of transporting BAs from 
the hepatocytes into bile (Stieger, 2011).  
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Knockout of Bsep in mice led to some unexpected findings. Bsep-null 
mice have decreased secretion of BAs into bile, but that did not affect bile flow in 
these mice, which is surprising because BAs are assumed to be the major driving 
force for bile flow. Although canalicular secretion of conjugated TCA and other 
hydrophobic BAs decreased in Bsep-null mice, the mice displayed only mild 
nonprogressive cholestasis. In humans, absence of BSEP causes a more severe 
progressive cholestasis. This species difference could be due to the presence of 
alternate BA canalicular transport system to transport hydrophilic BAs in mice 
and not in humans (Wang et al., 2001a). 
 BA transporters in cholangiocytes 
Cholangiocytes express the BA uptake transporter Asbt on the apical side to 
reabsorb BAs from bile and the BA efflux transporter Ostα-Ostβ on the basolateral side 
to transport the reabsorbed BAs into blood. The descriptions of Ostα/β are included in 
the next section. 
BA transporters on intestinal enterocytes 
Enterocytes express the BA uptake transporter Asbt on the brush border 
membrane and BA efflux transporters Ostα-Ostβ on the basolateral side. Asbt facilitates 
the reabsorption of conjugated BAs from the intestinal lumen into the enterocytes. Ostα-
Ostβ effluxes BAs absorbed from the intestinal lumen into the portal vein to be carried 
back to the liver.  
A. Apical sodium-dependent BA transporter (Asbt): The first step in BA 
reabsorption in the intestine is the active uptake of BAs across the apical 
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membrane of enterocytes by the transporter Asbt (Slc10a2) (Wong et al., 1994). 
In addition, Asbt is also localized on the apical membrane of large cholangiocytes 
in intrahepatic bile ducts and plays a role in cholehepatic circulation of BAs 
(Alpini et al., 1997; Lazaridis et al., 1997). The cholehepatic shunt/circulation was 
proposed to explain the hypercholeresis induced by some unconjugated BAs, 
and it refers to the reuptake of BAs from the bile duct lumen by cholangiocytes 
and the return of those BAs to hepatocytes (Yoon et al., 1986; Gurantz et al., 
1991).  
Human ASBT has a higher affinity for dihydroxy BAs and taurine- and 
glycine-conjugated BAs compared to trihydroxy BAs and unconjugated BAs 
(Craddock et al., 1998). Mutations in human ASBT, leads to primary BA 
malabsorption, refractory infantile diarrhea, steatorrhea, interruption of 
enterohepatic circulation of BAs, reduced plasma cholesterol levels and growth 
defects (Heubi et al., 1982; Oelkers et al., 1997). This underscores the 
importance of ASBT’s role in the reuptake of BAs from the intestine.  
Mice deficient in Asbt have decreased or very minimal intestinal BA 
absorption, 10- to 20-fold increase in fecal BA excretion, 80% reduction in BA 
pool size despite an increase in BA synthesis and a BA pool enriched in CA 
(Dawson et al., 2003).  Treatment with a BA-binding resin, cholestyramine did not 
further increase fecal BA excretion in these Asbt-null mice. This demonstrates 
that there is no or very minimal alternative (non-Asbt) mechanism for intestinal 
BA absorption in mice (Dawson et al., 2009). 
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B. Organic solute transporters (Ost): BAs that are reabsorbed from the intestinal 
lumen are translocated to the basolateral membrane by the intestinal bile acid 
binding protein and then effluxed across the basolateral membrane by the 
heterodimer Ostα-Ostβ transporters. Ostα and β were first cloned from a liver 
cDNA library of the marine skate (Wang et al., 2001b). The two subunits of the 
transporter Ostα and Ostβ are expressed together in enterocytes, hepatocytes, 
and cholangiocytes and localize to the basolateral membrane in cells that 
express Asbt on the apical membrane (Ballatori et al., 2005; Dawson et al., 
2005).  Interaction between the Ostα and Ostβ protein is required for the proper 
delivery to the plasma membrane, and heterodimerization is important for their 
transport function (Li et al., 2007). No inherited defects have been reported for 
the OSTα and OSTβ genes in humans (Dawson et al., 2009). 
Ostα-null mice have undetectable Ostβ levels. Absence of the basolateral 
BA transporters Ostα and β results in impaired BA transport across the 
basolateral membrane of enterocytes, altered feedback regulation of BAs, 
decreased hepatic BA synthesis leading to increased plasma cholesterol levels 
and decreased BA pool size (Rao et al., 2008).  
1.2.5   Regulation of BA synthesis 
Early research revealed that cholesterol and BAs in portal blood regulate the 
synthesis of primary BAs. Later, it was found that cholesterol feeding, BA feeding, and 
cholestyramine treatment could induce the activity of the enzyme cholesterol 7α-
hydroxylase or Cyp7a1, which is the rate-limiting enzyme of primary BA synthesis 
(Danielsson and Sjovall, 1975; Russell, 2009). The 3’-untranslated region in the Cyp7a1 
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mRNA transcripts are unusually long and the mRNA has a very short half-life of about 
30 mins. BAs via the BA response element present on the 3’-untranslated region can 
reduce Cyp7a1 mRNA stability (Agellon and Cheema, 1997; Chiang, 2009).  
FXR was discovered as an orphan receptor that forms a heterodimer complex 
with RXR (Retinoid X receptor) and was activated by farnesol and its metabolites 
(Forman et al., 1995). In 1999, three laboratories found BAs to be endogenous ligands 
of this orphan nuclear receptor, and by binding to FXR, BAs were able to regulate their 
own synthesis, transport and cholesterol metabolism (Makishima et al., 1999; Parks et 
al., 1999; Wang et al., 1999)  
In humans, functional variants of FXR have been associated with susceptibility to 
developing intrahepatic cholestasis of pregnancy and cholesterol gallstone formation 
(Van Mil et al., 2007; Kovacs et al., 2008). Synthetic FXR agonists such as INT-747, 6-
ECDCA (6α-ethyl-chenodeoxycholic acid) and GW4064 protect animal models of 
cholestasis, liver fibrosis, and diabetes (Pellicciari et al., 2002; Liu et al., 2003; Fiorucci 
et al., 2004; Zhang et al., 2006; Gadaleta et al., 2010). Hence, FXR agonists are 
considered potential therapeutic drugs. FXR present in the liver and FXR present in the 
ileum can both regulate enzymes involved in BA synthesis and BA transporters. 
A) FXR-SHP-LRH-1 liver pathway: FXR is a nuclear receptor activated by BAs that 
plays a critical role in the feedback regulation of BA synthesis as well as BA-
mediated regulation of glucose and lipid homeostasis. When BA concentrations 
increase in the enterohepatic circulation, the excess BAs binds to the nuclear 
receptor FXR in hepatocytes, and that leads to an increase in expression of short 
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heterodimer partner (SHP), an atypical nuclear receptor lacking a DNA binding 
domain. SHP then binds to and antagonizes the binding of the transcription factors 
liver receptor homolog-1 (LRH-1) and hepatocyte nuclear receptor 4α (HNF4α) to 
the promoter region of the target gene Cyp7a1, thus repressing the expression of 
Cyp7a1 and decreasing BA synthesis (Chiang, 2009) (see Fig.1.3, pathway I). Other 
target genes of FXR signaling in liver include suppression of Cyp8b1, and induction 
of BSEP and Ostα-Ostβ transporters.  
Dr. Gonzalez’s group has generated liver specific FXR-null mice and 
compared them to whole-body FXR-null mice to understand the importance of liver-
specific FXR regulation in BA homeostasis.  From that mouse model, it is known that 
Cyp8b1, Bsep and SHP are targets of FXR activation in the liver, whereas Cyp7a1 is 
not (Kim et al., 2007; Kong et al., 2012).  
FXR-FGF15/19-FGFR4/β-klotho intestinal pathway: Excess BAs also bind to the 
nuclear receptor FXR in the ileum, which leads to an increase in synthesis and 
secretion of fibroblast growth factor 15 (Fgf15) in mice (or FGF19 in humans). Fgf15 
secreted from the intestine, reaches the liver and suppresses BA synthesis by binding 
to the heterodimer receptor composed of FGF receptor 4 (FGFR4) and β-klotho 
expressed on hepatocytes. Activation of the FGFR4 + β-klotho complex stimulates the 
c-jun N-terminal kinases (JNK) and extracellular-signal-regulated kinase (ERK) 
pathways and SHP, eventually suppressing Cyp7a1. Using an intestinal specific FXR-
null mouse model, it was demonstrated that FXR regulation in the intestine is important 
for hepatic Cyp7a1 regulation (see Fig.1.3, pathway II).  
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Fig.1.3. Schematic diagram depicting BA signaling through FXR (pathway I and II) and 
TGR5 (pathway III, IV and V). 
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Targets of intestinal FXR regulation include Fgf15, SHP, Ileum BA binding 
protein (IBABP), and organic solute transporter Ostα-Ostβ in the ileum and hepatic 
Cyp7a1 (Kim et al., 2007; Matsubara et al., 2013). 
1.2.6   BA signaling through TGR5   
TGR5, also known as M-BAR (Membrane-bound BA receptor) or Gpbar-1 (G 
protein-coupled BA receptor) or BG37 is a plasma membrane-bound G protein-coupled 
BA receptor. Two independent groups discovered TGR5 by searching GenBank 
database for DNA sequence coding for novel GPCRs. BAs are the endogenous ligand 
for TGR5, and upon binding to the receptor, increases intracellular cAMP (Maruyama et 
al., 2002; Kawamata et al., 2003). 
TGR5 was found to be expressed ubiquitously in human tissues including heart, 
skeletal muscle, spleen, kidney, liver, small intestine, colon, placenta, leukocytes, 
thymus, and lung (Maruyama et al., 2002). In mice, TGR5 is expressed in jejunum, 
stomach, kidney, spleen, lung, white and brown adipose tissue, muscle, brain, heart, 
enteroendocrine cells in ileum and colon, gallbladder epithelial cells, sinusoidal 
endothelial cells, and kupffer cells in liver (Maruyama et al., 2006; Vassileva et al., 
2006; Keitel et al., 2007; Keitel et al., 2008; Reimann et al., 2008; Keitel et al., 2010). 
TGR5 gene variants have been identified in patients with primary sclerosing 
cholangitis, which is an inflammatory disease of the bile ducts, indicating that TGR5 
may contribute to disease susceptibility (Keitel and Haussinger, 2012). 
TGR5 agonists such as 6α-ethyl-23(S)-methyl-cholic acid (EMSA or INT-777) are 
promising drug candidates to treat metabolic disorders such as type 2 diabetes, obesity, 
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and steatohepatitis as they improve glucose tolerance and reduce inflammation and 
steatosis in mice (Keitel and Haussinger, 2012).  
TGR5 activation and GLP-1 secretion 
  TGR5 can promote glucagon-like peptide-1 (GLP-1) secretion from the murine 
enteroendocrine cell line STC-1 upon activation by BAs (Katsuma et al., 2005; Thomas 
et al., 2009). Patients treated with a BA-binding resin to reduce cholesterol levels also 
had improved glycemic control, and these BA-binding resins also improved 
hyperglycemia in rodent models of obesity (Kobayashi et al., 2007; Chen et al., 2010). 
TGR5 overexpressing mouse models demonstrate enhanced GLP-1 secretion and 
insulin release in response to a glucose load, and TGR5-null mice have impaired 
glucose tolerance (Thomas et al., 2009). Thus, BAs through their receptor TGR5 
regulate GLP-1 release and subsequently regulate glucose homeostasis (see Fig.1.3, 
pathway III). 
Oral administration of glucose results in more insulin release compared to 
intravenous glucose administration. Glucagon-like peptide-1 (GLP-1) is an incretin or 
gut derived hormone that is released in response to nutrient sensing and increases the 
insulin release after a meal. GLP-1 is a potent stimulator of insulin release and also 
reduces gastric motility, suppresses appetite, slows gastric emptying, increases hepatic 
fatty acid oxidation, and reduces hepatic gluconeogenesis. 
GLP-1 discovery. GLP-1 was discovered after cloning and sequencing 
mammalian proglucagon genes and cDNAs (Mojsov et al., 1987). The levels of 
intracellular cAMP and activation of cAMP/PKA signaling are major determinants of 
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intestinal proglucagon gene expression. The proglucagon mRNA is translated into a 
single 180 amino acid precursor protein that undergoes tissue specific posttranslational 
processing to produce specific peptides in pancreas, intestine, and brain (Drucker and 
Brubaker, 1989; Drucker et al., 1994).  
GLP-1 biosynthesis. Prohormone convertase 1 (PC1) is important for 
proglucagon processing in the intestine and PC1-null mice have a marked decrease in 
posttranslational products of the proglucagon gene (Ugleholdt et al., 2006). 
Posttranslational products of proglucagon in the enteroendocrine cells of the intestine 
are: glicentin, oxyntomodulin, GLP-1, intervening peptide-2, and GLP-2. The 
physiological actions of glicentin and the intervening peptide-2 are not known. 
Oxyntomodulin inhibits gastrointestinal secretion and motility, stimulated pancreatic 
secretions and glucose uptake. GLP-2 up-regulates intestinal glucose transport, and 
stimulates cell proliferation and inhibits apoptosis in the intestinal crypt compartment 
(Baggio and Drucker, 2007).  
GLP-1 forms. Multiple forms of GLP-1 are secreted in vivo: GLP-1 (1-37) and 
GLP-1 (1-36) NH2 are inactive, whereas GLP-1 (7-37) and GLP-1 (7-36) NH2 are 
biologically active and are products of PC1/3 cleavage (Baggio and Drucker, 2007). The 
enzyme peptidyl-glycine α-amidating monooxygenase is responsible for the addition of 
the amide group to GLP-1, which may enhance the survival of GLP-1 in plasma 
(Wettergren et al., 1998). The major GLP-1 in human circulation is GLP-1 (7-36) NH2 
(Orskov et al., 1994). 
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GLP-1 clearance. GLP-1 (7-36) has a penultimate alanine residue and thus is 
rapidly inactivated by a ubiquitous proteolytic enzyme dipeptidyl peptidase-4 [(DPP-4) 
DPP-4 is also known as CD26] to bioinactive GLP-1 (9-36) amide or GLP-1 (9-37). 
DPP-4 is found lining the blood vessels near the intestinal mucosa adjacent to the sites 
of GLP-1 secretion; therefore GLP-1 has a half-life of 2 minutes due to the action of 
DPP-4 (Baggio and Drucker, 2007). The C-terminal degradation product of GLP-1, the 
nonapeptide GLP-1(28-36) amide, can also repress hepatic gluconeogenesis  involving 
the activation of the cAMP/PKA signaling pathway, and reduced body weight gain in 
diet-induced obese mice (Ip et al., 2013), raising concerns about the physiological 
action of the other degradation products of GLP-1. 
  GLP-1 receptor. GLP-1 receptor (GLP-1R) belongs to the class B family of 7-
transmembrane-spanning, heterotrimeric G-protein-coupled receptor. Upon activation 
there are increases in PKA activity, Akt and AMPK phosphorylation, and a PKA-
dependent increase in peroxisome proliferator-activated receptor α (PPARα) activity. 
GLP-1R is expressed in a wide range of tissues including pancreatic islets, kidney, 
stomach, intestine and several regions of the hypothalamus, and brain. The presence of 
GLP-1R in liver was questionable until a recent study demonstrated the presence of 
GLP-1R in both human and rodent hepatocytes, proving GLP-1 has a direct effect on 
hepatocytes (Svegliati-Baroni et al., 2011). 
Therapeutic use of GLP-1. GLP-1 has beneficial effects in the treatment of 
type-2 diabetes. Recent reports also suggest that GLP-1 can also be beneficial in 
treating fatty liver disorders. The only problem is the short half-life of GLP-1. Several 
strategies have been tried and tested to help sustain a therapeutic concentration of 
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GLP-1 in serum. The DPP4-inhibitor sitagliptin and GLP-1R agonist (or GLP-1 
mimetics) exenatide and liraglutide are licensed drugs to treat type 2 diabetes. They do 
not cause hypoglycemia like the insulin secretagogues, but they create concerns 
because of their proliferative effects in the pancreas. Another recent approach is the 
continuous expression of GLP-1 in vivo by a gene therapy strategy, and it has shown 
promise in maintaining normoglycemia and aids in the treatment of type-2 diabetes in 
rodent models (Lee et al., 2007). 
TGR5 regulation of energy expenditure 
BAs bind to TGR5 expressed in brown adipose tissue and skeletal muscle, and 
increase intracellular cAMP, which in turn increases type 2 iodothyronine deiodinase 
(D2) activity. D2 is a thyroid hormone activating enzyme, which increases uncoupling 
protein (UCP)1 and UCP3, and increases energy expenditure as heat (Watanabe et al., 
2006). Treating diet-induced obese mice with a TGR5 agonist INT-777, reduced body 
weight gain and increased energy expenditure in brown adipose tissue by increasing 
the gene expression of  the genes D2, UCP1, and UCP3 (Thomas et al., 2009). Thus, 
activation of the BA receptor TGR5 influences energy expenditure in skeletal muscle 
and brown adipose tissue (see Fig.1.3, pathway IV).  
TGR5 and gallbladder 
TGR5 is expressed highly in the apical membrane of epithelial cells in the 
gallbladder (Keitel et al., 2009). Cholesterol precipitates in bile when its concentration 
increases relative to BAs and phospholipids and formation of cholesterol microcrystals 
from supersaturated bile is a critical step in gallstone formation. In supersaturated bile, 
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cholesterol is kept in vesicles consisting of cholesterol and phospholipids, and in TGR5-
null mice, the bile had an unexplained increase in the proportion of phospholipids, and 
thus kept cholesterol in vesicles and prevented microcrystal formation. (Vassileva et al., 
2006). Thus, TGR5-null mice that were fed a lithogenic diet were protected from 
cholesterol gallstone formation (Vassileva et al., 2006). 
In the gallbladder, TGR5 agonists increase cAMP levels and decrease 
intracellular chloride concentrations by increasing chloride secretion via the cAMP-
regulated chloride channel, that is the cystic fibrosis transmembrane conductance 
regulator (CFTR) (Keitel et al., 2009). TGR5-null mice have reduced gallbladder size. 
TGR5 agonist INT-777 increases gallbladder filling and gallbladder size in control mice 
but not in TGR5-null mice, illustrating that TGR5 activation promotes smooth muscle 
relaxation in gallbladder leading to gallbladder filling (Li et al., 2011) (see Fig.1.3, 
pathway V). 
1.3 Drug-metabolizing enzymes in liver 
A xenobiotic is any substance that is found in an organism that is not normally 
produced by the organism. Xenobiotic biotransformation/detoxification occurs via a 
series of enzyme-catalyzed processes that alter the physiochemical properties of 
xenobiotics. As it ‘filters’ the blood coming from the intestines, the liver is the primary 
organ responsible for detoxification. It contains a large number of enzymes dedicated 
for xenobiotic detoxification with the ultimate goal of making the xenobiotic more water-
soluble, and hence easier to eliminate from the body. These enzymes are called drug-
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metabolizing enzymes and can be classified as phase-1 and phase-2 enzymes 
(Parkinson and Ogilvie, 2013). 
1.3.1 Phase-1 enzymes 
Phase-1 enzymes perform hydrolysis, reduction, and oxidation reactions and as 
a consequence, this either increases or decreases the toxicity of a xenobiotic. Some 
examples of phase-1 drug metabolizing enzymes are summarized below: 
Carboxylesterases. Carboxylesterases (Ces) are enzymes with broad substrate 
specificities that cleave carboxylic esters to the corresponding alcohol and carboxylic 
acid. Ces help hydrolyze prodrugs with ester groups (increases hydrophilicity of drug) 
such as the cancer chemotherapeutic drug CPT-11 to its active form SN38 (Redinbo 
and Potter, 2005). 
Epoxide hydrolases. Epoxide hydrolases (Ephx) catalyze the addition of water 
to epoxides to form dihydrodiols. Ephx play an important role in detoxifying electrophilic 
epoxides that could bind to proteins and nucleic acids causing cell damage and genetic 
mutations. Ephx1 is a microsomal enzyme whereas Ephx2 is a soluble enzyme 
(Seidegard and Ekstrom, 1997).  
Aldo-keto reductases. Aldo-keto reductase (Akr) enzymes are cytosolic 
NADPH-dependent oxidoreductases that catalyzes the reduction of aldehydes and 
ketones to primary and secondary alcohols respectively (Chen and Zhang, 2012). 
Quinone reductases. Quinone reductase (Nqo) is a cytosolic, NADPH-
dependent enzyme. Nqos can catalyze a two-electron reduction and detoxify a quinone 
to a hydroquinone or catalyze a one-electron reduction and convert a quinone into a 
semiquinone free radical (Parkinson and Ogilvie, 2013).  
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Aldehyde dehydrogenases.  Aldehyde dehydrogenase (Aldh) enzymes, as the 
name suggests catalyze the oxidation of aldehydes such as acetaldehyde to carboxylic 
acids (acetate) and water. The mitochondrial Aldh2 and cytosolic Aldh1a1 are 
responsible for ethanol clearance. Polymorphisms in ALDH2 gene result in loss of 
enzyme activity and lead to the alcohol flushing syndrome (Stagos et al., 2010). 
Aldehyde oxidases. Aldehyde oxidase (Aox) is a cytosolic molybdozyme drug 
metabolizing enzyme. Aox are homodimers and require FAD for their activity. 
Substrates of Aox include xenobiotics with aldehyde groups, nitro/nitroso groups or 
heterocyclic moieties (Pryde et al., 2010).  
Flavin monooxygenases. Flavin monooxygenase (Fmo) is a FAD-containing 
monooxygenase that catalyzes NADPH-dependent N- or S-oxygenation of xenobiotics 
that possess heteroatoms. Many reactions catalyzed by Fmos can also be catalyzed by 
cytochrome P450s.  Fmos are found in the endoplasmic reticulum (Cashman, 2005) 
Cytochrome P450s. Cytochrome P450 (Cyp) enzymes are responsible for 75-
80% of all phase-1 drug metabolism reactions and for the clearance of 65-70% of 
clinically used drugs. Cyp enzymes are grouped into families based on their amino acid 
homology. The first three families (Cyp1, Cyp2, and Cyp3) are generally involved in the 
metabolism of xenobiotics, and Cyp families with higher numbers are usually involved in 
endobiotic metabolism (Sim and Ingelman-Sundberg, 2010). Cyp enzymes are found in 
the endoplasmic reticulum (most important for xenobiotic metabolism) and in 
mitochondria (most important for endobiotic metabolism). NADPH-cytochrome P450 
reductase (POR) is the obligate redox partner of all Cyps. Deletion of the POR leads to 
suppression of all Cyp enzyme activity (Gu et al., 2003). 
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1.3.2 Phase- 2 enzymes 
Phase-2 enzymes perform conjugation reactions that generally results in 
decreased toxicity of xenobiotics. Furthermore, conjugation in general markedly 
increases the water-solubility, and promotes the excretion of the xenobiotic (exceptions 
include methylation and acetylation). The major phase-2 enzymes in liver include 
uridinediphosphate (UDP)-glucuronosyltransferases, sulfotransferases, and glutathione 
S-transferases. 
UDP-glucuronosyltransferases (UGTs). UGTs are enzymes found in the 
endoplasmic reticulum and cytosol, that catalyze the transfer of a glucuronic acid from 
the cosubstrate UDP-glucuronic acid (UDPGA) to the xenobiotic with functional groups 
such as aliphatic alcohols or phenols, carboxylic acid, primary or secondary amines, 
and free sulfhydryl groups.  Glucuronide conjugates of xenobiotics are polar and are 
eliminated in urine or bile. If eliminated in bile, some gut bacteria with the enzyme β-
glucuronidase can hydrolyze the glycosidic bond between the glucuronic acid and the 
xenobiotic, thus delaying the elimination of the xenobiotic because it might enter the 
enterohepatic circulation (Parkinson and Ogilvie, 2013). 
Sulfotransferases (Sults): Sults catalyze the transfer of a sulfonic acid group 
from the cofactor 3’-phosphoadenosine-5’-phosphosulfate (PAPS) to the xenobiotic with 
an alcohol functional group. Sults can be either in the cytosol or bound to the golgi 
membranes. However, the cytosolic Sults are responsible for the sulfation of drugs and 
other xenobiotics. Sulfonic acid conjugated xenobiotics are excreted mainly in urine 
(Parkinson and Ogilvie, 2013). 
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Glutathione-S-transferases (Gsts): Gsts are enzymes that catalyze the transfer 
of the sulfhydryl group from the cofactor glutathione (GSH) to xenobiotics with halide, 
sulfate, sulfonate, phosphate, or a nitro group attached to an allylic or benzylic carbon 
atom, arene or alkene oxides, or electrophilic heteroatoms (O, N, and S). Gsts are 
localized in the cytosol (involved in xenobiotic metabolism), endoplasmic reticulum or in 
the mitochondria. The cofactor GSH is a tripeptide composed of glycine, cysteine, and 
glutamic acid. Glutamate-cysteine ligase catalytic subunit (Gclc) is the rate limiting 
enzyme of glutathione synthesis (Parkinson and Ogilvie, 2013).  
 
1.3.3 Regulation of hepatic drug metabolizing enzymes  
Nuclear receptors as xenosensors. Nuclear receptors are proteins found in the 
cytosol or nucleus of cells that upon activation act as transcription factors and induce 
the expression of a battery of its target genes. Some nuclear receptors act as sensors 
that can monitor the presence of a xenobiotic and induce drug metabolizing enzymes 
and transporters to detoxify and eliminate the xenobiotic. Some xenobiotics activate the 
xenobiotic sensor and thus induce the expression of the gene and subsequent drug 
metabolizing enzyme. 
The xenobiotic sensors that can regulate hepatic drug metabolizing enzymes 
include steroid receptors such as estrogen and androgen receptors; nonsteroid 
receptors, such as constitutive androstane receptor (CAR, NR1I3), pregnane X receptor 
(PXR, NR1I2), and peroxisome proliferator-activated receptor α (PPARα, NR1C1); 
transcription factor, aryl hydrocarbon receptor (Ahr); and oxidative stress sensor, 
nuclear factor erythroid 2-related factor 2 (Nrf2, Nfe2L2). CAR, PXR, and PPARα 
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function by heterodimerizing with the retinoid X receptor (RXR, NR2B1). Ahr functions 
by binding to the aryl hydrocarbon receptor nuclear translocator (ARNT) (Omiecinski et 
al., 2011; Aleksunes and Klaassen, 2012). Table 1.2 shows a list of some target genes 
of xenosensors (Aleksunes and Klaassen, 2012). 
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Table 1.2 Examples of xenosensor target genes. 
Xenosensor Examples of target genes 
Ahr Cyp1a1, Nqo1, Aldh7a1, Ugt1a1, Ugt1a6, Ugt1a9, Sult5a1, and Gstm3 
CAR 
Cyp2b10, Aldh1a1, Aldh1a7, Ugt1a1, Ugt2b34, Sult1e1, Sult3a1, 
Sult5a1, Papps2, Gsta1, Gsta4, and Gstm1-4 
PXR Cyp3a11, Ugt1a1, Ugt1a5, Ugt1a9, Gsta1, and Gstm1-3 
PPARα Cyp4a14, Aldh1a1, mGst3, and Gstm4 
Nrf2 Nqo1, Aldh1a1, Gsta1, Gsta4, Gstm1-4, and mGst3 
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CHAPTER 2 
STATEMENT OF PURPOSE 
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Statement of purpose 
BAs are hormones; they circulate in the blood and regulate host physiology by 
activating the FXR and TGR5 receptors. The diversity of BAs in the circulation is 
influenced by their metabolism by the liver as well as by gut bacteria. Similarly, the 
disposition of drugs and other xenobiotics are also influenced by metabolism of the 
drugs by the liver as well as by gut bacteria. 
There is a growing appreciation of gut bacteria as being an influential player in 
human physiology. Dysbiosis or alterations in the gut bacterial community are 
associated with many diseases. Altering gut bacteria by probiotics, prebiotics, and by 
fecal transplantation is viewed as a valuable therapeutic strategy for diseases 
associated with dysbiosis.  Alterations in gut bacteria will result in alterations in the host 
BA profile and the host drug metabolizing capacity.  
Mouse models have shed light on the players and pathways involved in BA and 
drug metabolism. To understand how certain bacteria regulate BA and drug 
metabolism, it is important to know how BAs and drug metabolism are altered in GF 
mice, in which gut bacteria are absent. Studying GF mice will reveal target genes that 
are altered by gut bacteria. Therefore, the objectives of this dissertation are to: 
1. Determine the alterations in BA metabolism and BA signaling in GF mice. 
2. Determine the alterations in hepatic drug metabolizing enzymes at the 
transcriptome level in GF mice. 
In Specific Aim 1, I determined the changes in BA homeostasis and BA 
signaling in GF mice. This was accomplished by establishing a GF animal facility to 
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breed and raise GF mice. The BA composition in the various BA enterohepatic tissue 
compartments (liver, gallbladder bile, ileum, and serum) and feces were compared 
between CV and GF mice. Chapter 4 summarizes the differences in BA composition in 
the different tissues and mRNA expression of 1) enzymes involved in BA synthesis, 2) 
BA transporters, and 3) genes involved in BA feedback regulation in CV and GF mice.  
Further, Specific Aim 1 also involved determining the differences in BA 
mediated TGR5 signaling in CV and GF mice by quantifying the downstream targets of 
TGR5 receptor activation. A striking observation was that GF mice have enlarged 
gallbladders, a phenomenon that was demonstrated to be possibly due to TGR5 
activation. Another major observation regarding BAs in GF mice was the increase in 
UDCA, which so far was thought to be a secondary BA made with help of gut bacteria. 
Because GF mice do not have gut bacteria to synthesize secondary BAs, our findings 
suggest that UDCA most likely must be a primary BA made in the livers of mice. 
To further support this suggestion, I studied the formation of UDCA by incubating 
microsomal fractions from livers of both CV and GF mice with other primary BAs, to 
determine whether enzymes present in the liver microsomes can biotransform primary 
BAs to UDCA. Chapter 4 also describes the observations that demonstrate that this is 
indeed the case and support the finding that UDCA is a primary BA in mice. 
In Specific Aim 2, I determined the alterations in hepatic drug metabolizing 
enzymes at the transcriptome level by quantifying their mRNA levels in the livers of GF 
and CV mice by RNA-Seq. Chapter 5 describes the observed differences in mRNA 
expression of phase-1 and phase-2 enzymes. To determine whether these mRNA 
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changes resulted in changed enzyme activities in vivo, I then performed the 
pentobarbital sleeping test in GF and CV mice. 
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CHAPTER 3 
MATERIALS AND METHODS 
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3.1 Germ-free isolator, supplies and sterility testing 
Vinyl flexible film isolators were purchased from Class Biologically Clean Ltd. 
(Madison, WI) to house the GF mice (Fig 3.1.A, B). The GF mice received autoclaved, 
irradiated Harlan Sani chips (#7990.BG Irradiated Teklad Sani Chips, Harlan Teklad, 
Madison, WI) as bedding and autoclaved paper towels or autoclaved nestlets as 
enrichment. The GF mice received autoclaved breeder or regular chow (autoclavable 
Rodent diet # 5K67, or autoclavable mouse breeder diet # 5021, Labdiet, Richmond, IN) 
and autoclaved water. The autoclave conditions for feed were standardized in Dr. Dan 
Peterson’s Germ-free animal facility at the University of Nebraska to minimize nutrient 
loss from food and prevent vitamin deficiency. The supplies were autoclaved and 
transferred using a supply cylinder (Fig 3.1.C, D).  
The GF status of the mice were monitored by sampling the feces and water in 
the drinking bottles and culturing them to detect the presence of bacteria in the following 
ways : 1) Fluid thioglycolate medium at 37°C for a week (detects facultative anaerobes) 
(Fig 3.2.A), 2) Brucella agar with 5% horse blood plates and placing them in Anaerobic 
pouches at 37°C for a week (detects anaerobes) (Fig 3.2.B), 3) Sheep blood agar plates 
at 37°C for a week (detects enterobacteria) (Fig 3.2.C) and 4) LB agar plates at room 
temperature for a week (detects environmental bacteria) (Fig 3.2.D). Ammonia is 
released from the bacterial breakdown of urea in urine, therefore ammonia levels were 
monitored in the germ-free room using ammonia test strips (Fig 3.2.E).   
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Fig 3.1. Pictures of the GF isolator and supply cylinder. (A) Front view of the germ-
free isolator. (B) Side view of the germ-free isolator. (C) Front view of the supply 
cylinder with autoclaved cage units. (D) Side view of the supply cylinder. 
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Fig 3.2. Representative pictures of the results of Sterility Testing. Feces from GF 
mice and water from their drinking bottles were tested routinely for the presence of 
bacteria. The results obtained with GF and CV mice are shown. (A) Fluid thioglycolate 
medium incubated for at 37°C for a week. (B) Brucella agar with 5% horse blood plates 
incubated in anaerobic pouches at 37°C for a week.  (C) Sheep blood agar plates 
incubated at 37°C for a week, and (D) LB agar plates incubated at room temperature for 
a week. (E) Ammonia test strips representing ammonia levels in the GF and CV mice 
room. GF represents germ-free mice and CV represents conventional mice. 
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3.2 Animals 
All mice used in the studies were about 3-months old unless otherwise 
mentioned. All mice were housed in an AAALAC (Association for Assessment and 
Accreditation of Laboratory Animal Care International)-accredited facility at the 
University of Kansas Medical Center, with a 14-h light/10-h dark-cycle, in a temperature-
and humidity-controlled environment, and ad libitum access to water. The initial 
breeding colony of GF C57BL/6J/UNC mice was established with mice purchased from 
the National Gnotobiotic Rodent Resource Center (University of North Carolina, Chapel 
Hill). All conventional mice were purchased from Jackson Laboratories and received 
autoclaved rodent diet and autoclaved water for a week before and during the study. All 
animal experiments were approved by the Institutional Animal Care and Use Committee 
at the University of Kansas Medical Center. 
3.3 Chemicals and reagents 
The sources of individual BA standards and internal standards were described 
previously by Zhang and Klaassen (Zhang and Klaassen, 2010). The monoclonal 
mouse anti-rat Cyp2b1/2b2 antibody, which also detects mouse Cyp2b10, was 
purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). A Cyp3a11 antibody 
was a generous gift from Dr. Xiaochao Ma (University of Pittsburgh). Secondary 
antibodies were purchased from Sigma-Aldrich (St. Louis, MO). The glucagon-like 
peptide-1(GLP-1) total ELISA kit was purchased from EMD Millipore (St. Charles, MO). 
The fluid thioglycollate medium, brucella agar plates with 5% horse blood and anaerobic 
pouches were purchased from BD (Sparks, MD), sheep blood agar plates were 
purchased from Remel (Lenexa, KS) and ammonia strips were purchased from 
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Microessential Laboratory (Brooklyn, NY). All other chemicals and reagents, unless 
indicated otherwise, were purchased from Sigma-Aldrich (St. Louis, MO). 
3.4 Bile collection 
Five-month old CV and GF mice were used for bile collection. The protocol for 
bile duct cannulation and bile collection was standardized in our laboratory (Csanaky et 
al., 2011). Mice were anesthetized intraperitoneally with a ketamine/midazolam mixture 
(100 and 5 mg/kg, respectively), and the common bile duct of each mouse was 
cannulated through a high abdominal incision with the shaft of a 30-gauge needle 
attached to PE-10 tubing. Bile was collected in the dark for 40 mins into preweighed 
microcentrifuge tubes on ice. The volume of bile was determined gravimetrically, using 
the value 1 for specific gravity. 
3.5 Pentobarbital sleeping test 
The pentobarbital sleeping test was performed as described previously 
(Bjorkholm et al., 2009). Briefly, the anesthetic pentobarbital was injected 
intraperitoneally into CV and GF mice (50 mg/Kg), and the time between loosing and 
then regaining the righting reflex was quantified. 
3.6 Animal sacrifice and tissue collection 
All animal sacrifices and tissue collections were performed between 9:00 am and 
noon to minimize the variations in drug metabolizing enzyme gene expression and BA 
metabolism due to the circadian rhythm (Zhang et al., 2009; Zhang et al., 2011b).  
3.7 Bile acid extraction  
Internal standards (40 μg/mL d4-G-CDCA and 20 μg/mL d4-CDCA in MeOH) 
were added to the samples, and BAs were extracted from serum, gallbladder bile, livers, 
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biliary bile, ileum, and feces using methods reported previously by our laboratory 
(Alnouti et al., 2008; Zhang and Klaassen, 2010; Zhang et al., 2011a; Zhang et al., 
2012).  
3.8 BA Quantification by Ultra-performance Liquid Chromatography-Tandem 
Mass Spectrometry (UPLC-MS/MS) 
BAs were quantified by UPLC-MS/MS using methods reported previously by our 
laboratory (Zhang and Klaassen, 2010). BAs quantified include: TCA, TDCA, TCDCA, 
TLCA, TUDCA, TαMCA, TMDCA, TβMCA, TωMCA, CA, DCA, CDCA, LCA, UDCA, 
αMCA, MDCA, βMCA, and ωMCA. The concentrations of individual BAs were summed 
to derive the concentrations of conjugated, unconjugated, and total BAs in each 
compartment. 
3.9 Preparation of hepatic microsomal fractions 
Hepatic microsomal fractions were isolated following a previously published 
protocol (MacGeoch et al., 1984). Briefly, livers were homogenized with a glass dounce 
homogenizer on ice with the homogenization buffer (sucrose, 250 mM; Tris-HCl, 50 
mM,   pH 7.4; EDTA (ethylenediaminetetraacetic acid), 1 mM; PMSF 
(phenylmethylsulfonyl fluoride), 0.2 mM) and centrifuged at 10,000xg for 25 min at 4°C. 
The supernatant was decanted and centrifuged at 100,000 g for 60 min at 4°C. The 
pellet was washed with potassium chloride Buffer (KCl buffer) (KCl, 150 mM; Tris-
HCl,10 mM, pH 7.4; EDTA,1 mM) and again centrifuged at 100,000xg for 60 min at 4°C. 
The resulting microsomes were resuspended in resuspension buffer (Tris-HCl, 10 mM, 
pH 7.4; EDTA, 1 mM; PMSF, 0.2 mM; glycerol, 20% w/v). Protein concentrations were 
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determined using the bicinchoninic acid assay (BCA assay) according to the 
manufacturer's instructions (Pierce Biotechnology, Rockford, IL). 
3.10 Microsomal biotransformation assay 
Final reaction mixtures contained CDCA, 200 µM; 0.5 mg of liver microsomal 
protein; 100 mM potassium phosphate buffer, pH 7.4 and 2 mM NADPH in a final 
volume of 250 µL. After preincubation of microsomal protein and CDCA for 10 min at 
room temperature, reactions were initiated with NADPH and incubated for 60 min at 
37°C. Reactions were terminated by adding 1 mL of ice-cold acetonitrile, dried under 
vacuum and resuspended in 80 µL of 50% methanol. Tubes were vortex-mixed and 
then centrifuged at 20,000xg for 10 min. The BAs were quantified using the method 
reported previously by our laboratory (Zhang and Klaassen, 2010). UDCA formation 
was reported as the ratio of the area under the curve (AUC) of UDCA formed to the 
AUC of CDCA used in the incubation mixture. 
3.11 GLP-1 quantification 
Total serum GLP-1 was quantified using an ELISA kit from EMD Millipore (St. 
Charles, MO) following the manufacturer’s protocol. The antibody pair used in the assay 
is specific for GLP-1(7-36) and (9-36), and has no cross-reactivity with GLP-2, GIP, 
glucagon or oxyntomodulin. 
3.12 RNA isolation 
Total RNA was isolated from tissues using RNA Bee reagent (Tel-Test Inc., 
Friendswood, TX) following the manufacturer's protocol. The concentration of total RNA 
in each sample was quantified spectrophotometrically at 260 nm. Quality of RNA was 
assessed by running the sample on a denaturing agarose gel and visualizing two 
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discrete 18S and 28S ribosomal RNA bands, with the 28S band double the intensity of 
the 18S band. 
3.13 Multiplex Suspension Assay 
The mRNAs of the BA biosynthetic enzymes and BA transporters in liver and 
ileum described in Chapter 4 were quantified using Panomics 2.0 QuantiGene Plex 
technology (Panomics/Affymetrix Inc., Fremont, CA), following the manufacturer’s 
protocol. Individual gene information can be found on Panomics web site 
(http://www.panomics.com) with Panel numbers 21330 and 21383. Fluorescence was 
analyzed using a Bio-Plex 200 system array reader with Luminex 100 X-MAP 
technology, and data were acquired using Bio-Plex data manager software 5.0 (Bio-
Rad, Hercules, CA). The mRNAs of target genes were normalized to the housekeeping 
gene 60S ribosomal protein L13a (Rpl13a). 
3.14 cDNA library preparation and RNA-sequencing 
The cDNA library preparation and sequencing of the transcriptome were 
performed with the help of the KUMC-Genome Sequencing Facility. The cDNA libraries 
from total RNA samples were prepared using an Illumina TruSeq RNA sample prep kit 
(Illumina, San Diego, CA). The average size of the cDNAs were approximately 160bp 
(excluding the adapters).  The cDNA libraries were validated for RNA-integrity and 
quantity using an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA) 
before sequencing. The cDNA libraries were clustered onto a TruSeq paired-end flow 
cell and sequenced (2×50bp) using a TruSeq SBS kit (Illumina, San Diego, CA) on the 
Illumina HiSeq2000 sequencer (KUMC – Genome Sequencing Facility) with a multi-plex 
strategy of 4 samples per lane. 
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3.15 RNA-Seq Data Analysis 
After the sequencing platform generated the sequencing images, the pixel-level 
raw data collection, image analysis, and base calling were performed by Illumina’s Real 
Time Analysis (RTA) software on a Dell PC attached to the HiSeq2000 sequencer.  The 
base call files (*.BCL) were converted to qseq files by the Illumina’s BCL Converter, and 
the qseq files were subsequently converted to FASTQ files for downstream analysis.  
The RNA-Seq reads from the FASTQ files were mapped to the mouse mm10 reference 
genome and the splice junctions were identified by TopHat.  The output files in BAM 
(binary sequence alignment) format were analyzed by Cufflinks to estimate the 
transcript abundance and the differential expression (Cuffdiff, FDR-BH<0.05). The 
mRNA abundance was expressed in FPKM (fragments per kilobase of exon per million 
reads mapped). 
3.16 Reverse Transcription and Real-time PCR Analysis 
Total RNA was transcribed to single-stranded cDNA using a High Capacity cDNA 
Reverse Transcription Kit 1001073 (Applied Biosystems, Foster City, CA). The resulting 
cDNA products were amplified by PCR, using Power SYBR Green PCR Master Mix in a 
7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). The 
primers for all real-time PCR reactions were synthesized by Integrated DNA 
Technologies (Coralville, IA). 
3.17 Western blotting 
Western blots of Cyp2b10 and Cyp3a11 were performed as previously described 
with minor modifications (Renaud et al., 2011). Liver homogenates were prepared in 
radioimmunoprecipitation assay buffer (RIPA buffer) (Sigma-Aldrich, St. Louis, 
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MO). Protein concentrations were determined using the BCA assay reagents according 
to the manufacturer's instructions (Pierce Biotechnology, Rockford, IL). The samples 
were subjected to polyacrylamide gel electrophoresis and transferred onto a 
polyvinylidene difluoride (PVDF) membrane. Membranes were stripped and reprobed 
with β-actin antibody as the loading control. Proteins were detected using 
chemiluminescence (Pierce Biotechnology, Rockford, IL). Intensities of protein bands 
were quantified using Image J software (National Institutes of Health, Bethesda, MD). 
3.18 Statistical Analysis. 
Data are presented as mean ± SEM. Asterisks (*) represent significant 
differences between CV and GF mice, determined by Student’s t-test (p < 0.05). 
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CHAPTER 4 
 ALTERATIONS IN BILE ACID HOMEOSTASIS AND BILE ACID SIGNALING   IN 
GERM-FREE MICE. 
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I. BACKGROUND 
  Bile acids are amphipathic cholesterol metabolites that are synthesized in the liver 
and secreted into bile. BAs are metabolized by gut bacteria to produce secondary BAs. 
Most of the BAs are reabsorbed from the intestine and enter the portal vein. Therefore, 
the BA profile in a person is the net result of the host hepatic enzyme activity and the 
gut bacterial enzyme activity. The BA profile is important because, in addition to helping 
in the absorption of fat and fat soluble vitamins, BAs also regulate host physiology. 
Therefore, alterations in gut bacteria can result in alterations in BA profiles leading to 
alterations in host physiology. The best animal model to study the function of gut 
bacteria is GF mice, and this dissertation provides the first information on BA 
homeostasis in GF C57BL/6 mice, which is the most widely used mouse strain for 
derivation of transgenic mouse models. 
 Therefore, the purpose of this study is to determine the alterations in BA 
homeostasis and BA signaling in GF C57BL/6 mice. The hypothesis I tested is that 
absence of gut bacteria would alter BA homeostasis. Therefore, a gnotobiotic facility 
was established to breed and raise GF mice used for the study.  
II. RESULTS 
A. General characterization of GF C57BL/6 mice 
The GF mice are a unique animal model as they are raised in an artificially clean 
enclosure, preventing exposure to microorganisms from the environment, food, and 
water. To better understand the differences between GF and CV mice it is important to 
characterize the general features of our GF mice. 
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The body weights of adult (3-months old) GF male mice are comparable to the body 
weights of adult CV male mice. However, adult GF female mice tend to be heavier than 
the CV mice at the same age (Fig. 4.1.A).  Both male and female GF mice have similar 
liver weights as CV mice (Fig. 4.1.B). The liver weight to body weight percentage is 
similar in male CV and GF mice but is lower in female GF mice compared to CV  ( 5.1% 
in CV and  4.6% in GF female mice) (data not shown). 
The GF mice display enlarged cecum and watery intestinal contents as previously 
described in the literature (Asano, 1969). The small and large intestines of GF mice 
weigh more than the intestines of CV mice (Fig.4.1.C and D) and the intestinal tract of 
GF mice is longer than in CV mice (representative pictures in Fig.4.1.E and F).  
The other distinguishing feature between GF and CV mice is the gallbladder. GF 
mice have a gallbladder that is about 4-5 fold larger than in CV mice (Fig. 4.1.G).  Bile 
was collected over a 40-min period from five-month-old male and female CV and GF 
mice.  Bile flow was increased in GF male mice compared to CV mice. In female GF 
mice, bile flow was increased compared to CV mice but due to increased variation 
within the group this difference was not statistically significant (Fig. 4.1.H). The 
increased bile flow could explain the increased gallbladder size seen in GF mice. 
B. BA concentrations in the various BA enterohepatic compartments of CV 
and GF mice.  
 Individual BAs have physicochemical properties based on their structure. Increase in 
BAs that have a -OH group in the 12 position (12-OH BAs such as CA and DCA), 
increase the cholesterol absorption across the intestine (Li-Hawkins et al., 2002).  
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Fig. 4.1. General characterization of GF mice. (A) Body weight of CV and GF mice. 
(B) Liver weight of CV and GF mice. (C) Small intestine weight of CV and GF mice. (D) 
Large intestine weight of CV and GF mice. (E) and (F) Representative pictures of the 
intestines of CV and GF mice. (G) Gallbladder weight of CV and GF mice, n = 10/group. 
(H) Bile flow in CV and GF mice, n = 3-6/group. Data are presented as means ± SEM. 
Asterisks (*) represent statistically significant difference between CV and GF mice (p < 
0.05) by Student’s t-test. CV - conventional mice, GF - germ-free mice, M - males, F- 
females. 
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  Taurine conjugation lowers the pKa of BAs, increases the aqueous solubility at 
the pH of the proximal intestine, and promotes a high intraluminal BA concentration 
leading to efficient solubilization of lipids and lipid-soluble vitamins (Setchell et al., 
2013). Therefore, in addition to quantifying total BAs (summation of individual BA 
concentrations), the total concentrations of 12-OH BAs and non 12-OH BAs as well as 
total concentrations of taurine-conjugated and unconjugated BAs were quantified. In 
general, GF mice had higher concentrations of BAs in all the tissue compartments 
tested but have lower concentration of BAs excreted in feces compared to CV mice. 
Female GF and CV mice had higher BA concentrations than the respective male mice.    
BAs in Serum: GF male and female mice have a 4-fold increase in total BAs in 
serum compared to CV mice (Fig. 4.2.A). This increase in total BAs in GF mice is due to 
an increase in primary BAs. Secondary BAs were not detected in GF mice, confirming 
that gut bacteria are absent in these mice. GF mice have increased total 12α-OH BAs 
(CA, DCA, and their taurine conjugates) and non 12α-OH BAs (BAs other than CA, 
DCA, and their taurine-conjugates) compared to CV mice. Gut bacteria are known to 
deconjugate taurine-conjugated BAs, therefore in GF mice there is an increase in 
taurine-conjugated BAs and a decrease in unconjugated BAs (Fig. 4.2.A).  
In serum of male and female GF mice, the concentration of taurine-conjugated 
primary BAs, Tα+βMCA, and TCA are higher, whereas the taurine-conjugated 
secondary BA, TωMCA are lower than in the CV mice (Fig. 4.2.B). In addition, female 
GF mice also have increased primary BAs, TUDCA, and TCDCA, and decreased 
secondary BA, TDCA, compared to CV mice. Most unconjugated BAs decrease in the 
serum of male and female GF mice compared to CV mice (Fig. 4.2.C).   
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Fig. 4.2. Concentrations of BAs in the serum of CV and GF mice.  (A) 
Concentrations of total BAs ( ), total 1 (primary) BAs and 2 (secondary) BAs, total 12α-
OH BAs (CA, TCA, DCA, and TDCA) and non 12α-OH BAs (all other BAs), total T-Conj 
(taurine- conjugated) and Unconj (unconjugated) BAs. (B) Concentrations of individual 
T-conj (taurine-conjugated) BAs. (C) Concentrations of individual Unconj (unconjugated) 
BAs. Data are presented as means ± SEM, n = 7-10 mice/group. Asterisks (*) represent 
statistically significant differences between CV and GF mice (p < 0.05) by Student’s t-
test. Dark blue and light blue bars represent CV and GF male mice; red and pink bars 
represent CV and GF female mice, respectively. CV- conventional mice. GF- germ-free 
mice. M- males. F- females.   
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Fig. 4.3. Proportion of individual BAs in the serum of CV and GF mice.  Proportions 
of individual BAs in serum of (A) conventional male mice, (B) germ-free male mice, (C) 
conventional female mice, and (D) germ-free female mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
The proportions of individual BAs in the serum of GF mice change markedly. T-
α+β MCA and TCA are the major BAs in the serum of GF male and female mice (Fig. 
4.3.B and D). T-α+β MCAs make up 7% and 19% of BAs in the serum of CV male and 
female mice respectively, but are 77% and 71% of the total BAs in the serum of GF 
male and female mice (Fig. 4.3.A, B, C, and D). 
BAs in Liver: Liver is responsible for the majority of BA synthesis. Interestingly, 
GF mice livers had a 2-fold higher concentration of primary BAs and total BAs, 
compared to CV mice. As expected, bacteria-derived secondary BAs are essentially 
absent in GF mice. GF mice have an increased non 12α-OH BAs, but not the 12α-OH 
BAs.  Both taurine-conjugated and unconjugated BAs are approximately twice as high in 
the livers of GF mice compared to CV mice (Fig. 4.4.A).  
GF male and female mice have increased taurine-conjugated primary BAs, such 
as Tα+βMCA and TUDCA, and decreased taurine-conjugated secondary BAs in the 
livers compared to CV mice. In addition, livers of GF male mice have increased TCDCA 
than CV mice (Fig. 4.4.B). 
Concentrations of βMCA in livers of GF male and female mice are higher than in 
CV mice. Unconjugated secondary BAs are essentially absent in the livers of GF mice 
in comparison to CV mice (Fig. 4.4.C). 
Proportions of the various BAs in livers of GF mice are altered. Tα+βMCA 
increase and form 71% and 69% of the total liver BAs in GF male and female mice, 
respectively compared to 24% and 29% of total BAs in CV male and female mice (Fig. 
4.5.A, B, C and D).  
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Fig. 4.4. Concentrations of BAs in the livers of CV and GF mice.  (A) 
Concentrations of total BAs ( ), total 1 (primary) BAs and 2 (secondary) BAs, total 12α-
OH BAs (CA,  TCA, DCA, and TDCA) and non 12α-OH BAs (all other BAs), total T-Conj 
(taurine-conjugated) and Unconj (unconjugated) BAs. (B) Concentrations of individual 
T-conj (taurine-conjugated) BAs. (C) Concentrations of individual Unconj (unconjugated) 
BAs. Data are presented as means ± SEM, n = 7-10 mice/group. Asterisks (*) represent 
statistically significant differences between CV and GF mice (p < 0.05) by Student’s t-
test. Dark blue and light blue bars represent CV and GF male mice; red and pink bars 
represent CV and GF female mice, respectively. CV- conventional mice. GF- germ-free 
mice. M- males. F- females.   
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Fig. 4.5. Proportion of individual BAs in the livers of CV and GF mice.  Proportions 
of individual BAs in livers of (A) conventional male mice, (B) germ-free male mice, (C) 
conventional female mice, and (D) germ-free female mice.  
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Interestingly, concentration of TUDCA, a known therapeutic secondary BA is 
increased in the livers of GF mice compared to CV mice (Fig. 4.4.B and Fig. 4.5.A, B, C 
and D). This suggests that in mice, TUDCA can also be synthesized in the liver and 
therefore is a primary BA.  
BAs in Bile: BAs formed in the liver are effluxed into bile. Therefore, it is not 
surprising that the BA composition of GF livers and GF bile is similar. Biliary excretion of 
total BAs in GF mice was 3-fold higher in male GF mice and 2-fold higher in female GF 
mice compared to CV mice (Fig. 4.6.A). This increase is due to an increase in primary 
BAs, because secondary BAs are again essentially absent. There is an increase in the 
concentration of total non 12α-OH BAs in the bile of male and female GF mice. Both 
taurine-conjugated and unconjugated BAs are increased in the bile of GF mice 
compared to CV mice (Fig. 4.6.A). 
Concentrations of primary conjugated BAs, such as Tα+βMCA, TCDCA, and 
TUDCA are higher in bile of both GF male and female mice compared to CV mice. As 
expected, the concentrations of secondary conjugated BAs such as, TωMCA, TDCA 
and TLCA are essentially absent in bile of both GF male and female mice compared to 
CV mice (Fig. 4.6.B). 
Concentrations of the primary unconjugated BAs (αMCA and CA) are decreased, 
whereas βMCA is increased in both male and female GF mice compared to CV mice. 
Again, the secondary unconjugated BAs (ωMCA, DCA and LCA) are essentially absent 
in bile of GF male and female mice (Fig. 4.6.C). 
The proportions of the various BAs in the bile of GF and CV mice are very 
different. Apart from the decrease in secondary BAs, the proportion of the primary BA,  
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Fig. 4.6. Concentrations of BAs in bile of CV and GF mice. BAs in bile are 
expressed as nMol/Kg body weight/min. (A) Concentrations of total BAs ( ), total 1 
(primary) BAs and 2 (secondary) BAs, total 12α-OH BAs (CA, TCA, DCA, and TDCA) 
and non 12α-OH BAs (all other BAs), total T-Conj (taurine-conjugated) and Unconj 
(unconjugated) BAs. (B) Concentrations of individual T-conj (taurine-conjugated) BAs. 
(C) Concentrations of individual Unconj (unconjugated) BAs. Bile was collected for 40 
mins from each mouse. Data are presented as means ± SEM, n =3-6 mice/group. 
Asterisks (*) represent statistically significant differences between CV and GF mice (p < 
0.05) by Student’s t-test. Dark blue and light blue bars represent CV and GF male mice; 
red and pink bars represent CV and GF female mice, respectively. CV- conventional 
mice. GF- germ-free mice. M- males. F- females.   
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Fig. 4.7. Proportion of individual BAs in the bile of CV and GF mice.  Proportions of 
individual BAs in bile of (A) conventional male mice, (B) germ-free male mice, (C) 
conventional female mice, and (D) germ-free female mice.  
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TCA also decreases from 47% and 44% in CV male and female mice to 14 and 18% in 
GF male and female mice, respectively. In contrast, Tα+βMCA which make up 29% of 
BAs in bile of CV male and female mice, are increased and form 83% and 78% of total 
BAs in the bile of GF male and female mice, respectively (Fig 4.6. A, B, C, and D). 
BAs in ileal tissue: Normally, BAs in the intestine are metabolized by gut 
bacteria, to their deconjugated form and/or to secondary BAs. The majority of BAs 
return to the liver via the portal circulation. Some of the unconjugated BAs can diffuse 
across the enterocytes, while the rest and in particular the conjugated BAs are taken up 
into enterocytes by Asbt across the apical membrane. Transport across the basolateral 
membrane is mediated by Ostα-Ostβ. Similar to the other tissue compartments, there 
are increased levels of primary and taurine-conjugated BAs, and decreased levels of 
secondary and unconjugated BAs in GF mice compared to CV mice (Fig. 4.8.A)  
Total BAs concentrations were 4-fold higher in male GF mice and 3-fold higher in 
female GF mice compared to their CV controls (Fig. 4.8.A). This suggests increased 
uptake of BAs from the intestinal lumen or decreased transport across the basolateral 
membrane. Similar to the other tissue compartments, there are increased levels of 
primary and taurine-conjugated BAs and decreased levels of secondary and 
unconjugated BAs in GF mice compared to CV mice (Fig. 4.8.A). 
Concentrations of the primary taurine-conjugated BAs, (Tα+βMCA, TCA, 
TCDCA, and TUDCA) are increased, whereas the concentrations of the secondary 
taurine-conjugated BAS (TωMCA, TMDCA, TDCA, and TLCA) are decreased in both 
male and female GF mice compared to CV mice (Fig. 4.8.B). Concentrations of both 
primary and secondary unconjugated BAs are lower in the ileal tissue of GF mice  
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Fig. 4.8. Concentrations of BAs in the ileal tissue of CV and GF mice.  (A) 
Concentrations of total BAs ( ), total 1 (primary) BAs and 2 (secondary) BAs, total 12α-
OH BAs (CA,  TCA, DCA, and TDCA) and non 12α-OH BAs (all other BAs), total T-Conj 
(taurine- conjugated) and Unconj (unconjugated) BAs, (B) Concentrations of individual 
T-conj (taurine-conjugated) BAs, and (C) Concentrations of individual Unconj 
(unconjugated) BAs. Ileal tissue refers to the last 1/3rd of the small intestine. Data are 
presented as means ± SEM, n = 7-10 mice/group. Asterisks (*) represent statistically 
significant differences between CV and GF mice (p < 0.05) by Student’s t-test. Dark 
blue and light blue bars represent CV and GF male mice; red and pink bars represent 
CV and GF female mice, respectively. CV- conventional mice. GF- germ-free mice. M- 
males. F- females.   
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Fig. 4.9. Proportion of individual BAs in the ileal tissue of CV and GF mice.  
Proportions of individual BAs in ileal tissue of (A) conventional male mice, (B) germ-free 
male mice, (C) conventional female mice, and (D) germ-free female mice.  
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compared to CV mice (Fig. 4.8.C). The proportions of BAs in the ileal tissue are altered 
in GF mice compared to CV mice. Tα+βMCA are increased to 78 and 75% of the total 
BAs in ileal tissue of GF male mice, compared to 28 and 38% in CV mice (Fig. 4.9.A, B, 
C, D). 
BAs in Feces: Mice were housed in individual metabolic cages and feces were 
collected over a 24-hr period. Generally, more than 90% of BAs in the intestinal lumen 
are reabsorbed from the intestine and the remaining BAs are excreted in feces. There 
was a 63% decrease in the amount of total BAs in feces of GF mice compared to CV 
mice, which is mainly due to the absence of secondary BAs (Fig. 4.10.A). This can in 
part be explained by an increased ileal uptake of BAs in the absence of gut bacteria in 
GF mice. Furthermore, the absence of gut bacteria for deconjugation also leads to 
increased levels of conjugated BAs in feces of GF mice (Fig. 4.10.A). 
The amount of primary taurine-conjugated BAs (TCA, Tα+βMCA, TCDCA, and 
TUDCA) are increased whereas the amount of the secondary conjugated BAs (TωMCA, 
TDCA, and TLCA) are decreased in the feces of GF mice (Fig. 4.10.B). The amount of 
all unconjugated BAs quantified in feces of GF mice, were much lower than CV mice 
(Fig. 4.10.C). 
Finally, the proportions of BAs in feces of GF mice are very different compared to 
CV mice. Tα+βMCA are increased and form 74% of the total BAs, compared to 5% in 
CV mice (Fig. 4.11.A and B).  
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Fig. 4.10. Concentrations of BAs in feces of CV and GF mice.  BAs are expressed 
as nMols/gram of feces. (A) Concentrations of total BAs ( ), total 1  (primary) BAs and 2   
(secondary) BAs, total 12α-OH BAs (CA,  TCA, DCA, and TDCA) and non 12α-OH BAs 
(all other BAs), total T-Conj (taurine-conjugated) and Unconj (unconjugated) BAs. (B) 
Concentrations of individual T-conj (taurine-conjugated) BAs. (C) Concentrations of 
individual Unconj (unconjugated) BAs. Mice were housed individually in metabolic 
chambers and feces were collected over 24 hrs. Data are presented as means ± SEM, 
n = 4 mice/group. Asterisks (*) represent statistically significant differences between CV 
and GF mice (p < 0.05) by Student’s t-test. Dark blue and light blue bars represent CV 
and GF male mice. CV- conventional mice. GF- germ-free mice. M- males.  
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Fig. 4.11. Proportion of individual BAs in feces of CV and GF mice.  Proportions of 
individual BAs in feces of (A) conventional male mice, and (B) germ-free male mice.  
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C. BA-related gene expression in livers and ileum of CV and GF mice 
The gene expression of BA biosynthetic enzymes, BA transporters, and genes 
involved in BA feedback regulation were quantified in liver and ileal tissue of GF mice 
and compared to CV mice.  
Enzymes involved in BA biosynthesis.  
The main enzymes involved in BA biosynthesis include Cyp7a1, Cyp7b1, 
Cypb8b1, Cyp27a1 and the BA conjugation enzymes BAL and BAAT. Cyp7a1 is the 
rate-limiting enzyme in BA synthesis and is responsible for the 7α-hydroxylation of 
cholesterol metabolites in the classic pathway of BA synthesis. The mRNA levels of 
Cyp7a1 are similar in livers of CV and GF male mice. However, in female mice Cyp7a1 
mRNA levels are about 50% of the levels detected in GF mice (Fig. 4.12). 
Cyp7b1 is the enzyme responsible for 7α-hydroxylation of cholesterol metabolites 
in the alternate pathway of BA synthesis. Cyp7b1 mRNA is decreased by 30% and 52% 
in livers of male and female GF mice, respectively, compared to CV mice (Fig. 4.12). 
This may be an attempt to decrease the alternate pathway of BA synthesis to ultimately 
decrease concentrations of BAs in the livers of GF mice.  
Cyp8b1, which is also known as sterol 12α-hydroxylase, is an important enzyme 
that is responsible for the 12α-hydroxylation of cholesterol to form CA. The mRNA levels 
of Cyp8b1 are decreased 32% in the livers of male GF mice and decreased 73% in 
livers of female GF mice compared to their CV controls (Fig. 4.12). This correlates well 
with the decrease in concentration of 12α-OH BAs (TCA and CA) in liver and the 
decrease in proportion of TCA to Tα + βMCA in livers of GF mice (Fig. 4.5.A, B, C, D).  
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Fig. 4.12. Gene expression of enzymes involved in BA synthesis in CV and GF 
mice.  mRNA  expression of genes involved in BA homeostasis in livers of male and 
female CV and GF mice. mRNA was quantiifed by beadplex  assay, n = 6/group. Data 
are presented as means ± SEM. Asterisks (*) represent statistically significant 
differences between CV and GF mice (p < 0.05) by Student’s t-test. CV - conventional 
mice, GF - germ-free mice, M - males, F - females. Dark blue and light blue bars 
represent CV and GF male mice, respectively. Red and pink bars represent CV and GF 
females, respectively. 
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Cyp27a1 is a mitochondrial enzyme that plays two important roles in BA 
synthesis: 1) it is responsible in the classical pathway for steroid side chain cleavage, 
that is to convert C27 cholesterol or its metabolites to C24 BAs, and 2) is also responsible 
for the first step in the alternate pathway of BA synthesis by generating oxysterols (25- 
and 27-hydroxycholesterol) from cholesterol.  The mRNA of Cyp27a1 decreased by 
15% in the livers of female GF mice compared to CV mice, but is similar in livers of 
male CV and GF mice.  
The enzyme BAL catalyzes the addition of CoA to BAs, and subsequently the 
enzyme BAAT conjugates BA-CoA to the amino acids taurine or glycine before BA 
secretion into bile. In GF mice, there is an increase in taurine-conjugated BAs compared 
to CV mice as GF mice lack gut bacteria that deconjugate BAs. The mRNA levels of 
BAL were decreased 15% and the mRNA levels of BAAT were decreased 19% in the 
livers of female GF mice compared to the CV controls. However, BAL and BAAT mRNA 
levels do not change in male GF mice compared to CV mice (Fig. 4.12). 
BA Transporters 
The main BA uptake transporters in livers are Ntcp and Oatp1b2, whereas Asbt 
is considered to be the main uptake system in ileum. BAs efflux into bile is mediated by 
Bsep, BAs efflux back into blood is mediated by Mrp3 and Mrp4 and BAs efflux into 
portal circulation is by Ostα-Ostβ in ileum.  
The hepatic BA transporters Ntcp and Oatp1b2 are responsible for the uptake of 
conjugated and unconjugated BAs, respectively, across the basolateral membrane of 
hepatocytes. In male GF mice, the mRNA of Ntcp increased 42% and the mRNA levels 
of Oatp1b2 increased 48%, compared to CV mice (Fig. 4.13.A). This increase in mRNA 
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of hepatic BA uptake transporters enable the liver to remove more BAs from the 
circulation, given that total BAs are higher in serum of both male and female GF mice. 
However, in female GF mice, the mRNA of Ntcp, and Oatp1b2 are similar to that in CV 
mice (Fig. 4.13.A).  
The mRNA of the major hepatic BA efflux transporter Bsep was decreased by 
11% in male GF mice but does not change in livers of female GF mice compared to 
their respective CV controls (Fig. 4.13.A).  The gene expression of Mrp2 increased by 
25% in livers of male GF mice but does not change in livers of female GF mice 
compared to their respective controls (Fig. 4.13.A).   
Asbt is the only known apical BA uptake transporter and the mRNA levels of Asbt 
increased by 154% in the ileum of male GF mice compared to CV mice (Fig. 4.13.B). 
This correlates well with the increased total BA concentrations in the ileal tissue and 
decreased total BA content in feces observed in the GF mice compared to CV mice 
(Fig. 4.8.A and Fig. 4.10.A). However, in females, there is no difference in expression of 
Asbt in both groups of mice.  
The ileal BA transporters Ostα and Ostβ mediate efflux of BAs into the portal 
circulation. There are no differences in the mRNA levels of Ostα and Ostβ in the ileal 
tissue of GF mice compared to CV mice. In male GF mice, although mRNA of Ostα 
increased by 46% compared to CV mice, the mRNA of Ostβ did not change (Fig. 
4.13.B).  
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Fig. 4.13. Gene expression of  BA transporters in CV and GF mice.  (A) mRNA  
expression of of BA transporters in the livers of male and female CV and GF mice. (B) 
mRNA  expression of BA transporters in the ileum of male and female CV and GF mice. 
mRNA was quantiifed by beadplex  assay, n = 6/group. Data are presented as means ± 
SEM. Asterisks (*) represents statistically significant differences between CV and GF 
mice (p < 0.05) by Student’s t-test. CV - conventional mice, GF - germ-free mice, M - 
males, F - females. Dark blue and light blue bars represent CV and GF male mice 
respectively. Red and pink bars represent CV and GF females, respectively. 
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Genes involved in BA feedback regulation 
BAs are known to regulate their own synthesis by binding to the intracellular BA 
receptor FXR that suppresses Cyp7a1, the rate limiting enzyme in BA synthesis. FXR is 
expressed both in liver and ileum. In liver, binding of BAs to FXR, results in an increase 
in SHP, which displaces Lrh-1 from the promoter region of Cyp7a1 and suppresses 
Cyp7a1 transcription. In the ileum, BA binding to FXR increases the secretion of Fgf15, 
which travels via the portal circulation to the liver and activates the hepatic receptor 
Fgfr4. It is known that activation of the Fgfr4 receptor, leads to an increase in SHP and 
subsequently also suppresses Cyp7a1. 
The only changes in the mRNA levels of genes involved in BA feedback 
regulation were increased mRNA levels of FXR and LRH-1 in the livers of male GF mice 
compared to their CV controls. However, this increase may not be biologically 
significant as there was no subsequent decrease in the mRNA of Cyp7a1 in the livers of 
male GF mice compared to CV mice (Fig. 4.14.A). There are no changes in the mRNA 
of the other important genes involved in BA feedback regulation through FXR activation 
(Fig. 4.14). 
 
D. Targets of TGR5 signaling in CV and GF mice 
The plasma membrane-bound G protein-coupled receptor TGR5 is activated by 
BAs which results in an increase in intracellular cAMP levels, which in turn activate the 
enzyme protein kinase A (PKA). PKA can increase or decrease the activity of target 
enzymes by direct phosphorylation.  
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Fig. 4.14. Expression of genes involved in BA feedback regulation  in CV and GF 
mice.  (A) mRNA  expression of genes involved in BA feedback regulation in livers of 
male and female CV and GF mice. (B) mRNA  expression of genes involved in BA 
fedback regulation in ileum of male and female CV and GF mice. mRNA was quantiifed 
by beadplex  assay, n = 6/group. Data are presented as means ± SEM. Asterisks (*) 
represent statistically significant differences between CV and GF mice (p < 0.05) by 
Student’s t-test. Dark blue and light blue bars represent CV and GF male mice, 
respectively. Red and pink bars represent CV and GF females, respectively. CV- 
conventional mice, GF- germ-free mice, M- males, F- females. 
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An increase in intracellular cAMP also results in activation of the transcription 
factor cAMP response element-binding protein (CREB), which increases the 
transcription of its target proteins. The major effects of TGR5 activation include 1) 
increased bile flow and gallbladder size (Li et al., 2011); 2) increased GLP-1 secretion 
from ileum (Katsuma et al., 2005) and, 3) increased energy expenditure as heat 
(Thomas et al., 2009) (Fig. 4.15 and Table 4.1).  
Bile flow and gallbladder size. GF mice have a 5-fold increase in gallbladder 
weight compared to CV mice (Fig. 4.16.A and B). In addition, bile flow was higher by 
44% in GF male mice compared to their CV controls (Fig. 4.16.C).  
GLP-1. Serum GLP-1 concentrations were quantified by ELISA (Millipore, MO). 
GLP-1 was minimally detectable in the serum of CV mice but the concentration in the 
serum of GF mice was clearly higher (Fig. 4.17.A). GLP-1 is a cleavage product of the 
proglucagon peptide in the ileum, and the enzyme responsible for this cleavage is 
prohormone convertase (PC1). The mRNA of PC1 was also significantly higher in GF 
mice compared to CV mice (Fig. 4.17.B). 
Genes involved in thermogenesis. Activation of TGR5 in brown adipose tissue 
and muscle increases the expression of type 2 iodothyronine deiodinase (D2), which 
subsequently increases energy expenditure as heat in the mitochondria. The mRNA of 
D2 was increased 3-fold in the brown adipose tissue of GF mice (Fig. 4.17.C), which 
suggests that the TGR5 receptor is activated in the brown adipose tissue of GF mice. 
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Pgc1α) is a 
transcription factor that regulates mitochondrial biogenesis. The mRNA of PGC1α also 
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                     Fig 4.15. Schematic diagram displaying the TGR5 signaling pathways. 
                                          
Table 4.1. Targets of TGR5 signaling 
 
Target organs Effect 
1 Gallbladder Increase gallbladder volume/weight 
2 Ileum Increase GLP-1 release 
3 Muscle Thermogenesis 
4 Brown fat Thermogenesis 
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Fig.4.16. Gallbladder weights in GF mice. (A) Representative pictures of the 
gallbladders of CV and GF mice. (B) Weights of the gallbladder in CV and GF mice, n = 
7-10 mice/group. (C) Bile flow in CV and GF mice, n = 3-6 mice/group. Data are 
presented as means ± SEM. Asterisks (*) represent statistically significant differences 
between CV and GF mice (p < 0.05) by Student’s t-test. CV - conventional mice, GF - 
germ-free mice, M – males. Dark blue and light blue bars represent CV and GF male 
mice, respectively. 
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Fig.4.17. Targets of TGR5 signaling. (A) Serum GLP-1 quantification by ELISA. 
mRNA quantification by RT-PCR in (B) ileum, (C) brown adipose tissue and (D) muscle. 
Data are presented as means ± SEM, n = 5/group. Asterisks (*) represent statistically 
significant differences between CV and GF mice (p < 0.05) by Student’s t-test. Conv - 
conventional mice, GF - germ-free mice, M – males. Red bars represent CV mice and 
blue bars represent GF mice, respectively. 
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increased in muscle and brown adipose tissue of GF mice (Fig. 4.17.C and D) which 
suggests increased thermogenesis occurring in the brown adipose tissue and muscle of 
GF mice compared to CV mice. 
E. UDCA synthesis by enzymes in mouse hepatic microsomes 
One of the striking findings of this study was that GF mice, without any gut 
bacteria, still synthesized UDCA, and had high TUDCA concentrations. TUDCA levels in 
serum were not detectable in CV male mice, but could easily be quantified in GF mice 
(Fig. 4.18.A). Compared to CV mice, GF mice had a 3-fold increase in TUDCA in the 
liver and bile (Fig. 4.18.B and C), and a 6-fold increase in TUDCA in the ileal tissue and 
in feces (Fig. 4.18.D and E).  Therefore, I wanted to test the hypothesis that microsomal 
enzymes prepared from GF mice livers can synthesize UDCA from a primary BA. Using 
a traditional biotransformation assay (Description in Chapter 3), I found that incubating 
CDCA with hepatic microsomal protein from GF mice resulted in the appearance of a 
detectable peak with the same retention time and mass as the UDCA standard (Fig. 
4.19). No UDCA peak was detected if the assay mixture did not contain CDCA or if CA 
was used instead of CDCA (data not shown), clearly suggesting that UDCA is a primary 
BA.  
  Because the concentration of TUDCA was higher in livers of GF mice compared to 
CV mice, I next wanted to determine whether hepatic microsomal enzymes from GF 
mice would synthesize more UDCA than enzymes isolated from CV mice. Therefore, I 
incubated the same concentration of hepatic microsomal protein from both CV and GF 
mice with CDCA in the biotransformation assay and analyzed the products.  
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Fig. 4.18. UDCA concentrations in CV and GF mice.  Bile acid concentrations in (A) 
serum, (B) liver, (C) bile, (D) ileal tissue, and (E) feces of CV and GF mice. Data are 
presented as means ± SEM. Serum and liver n = 10/group; ileal tissue n = 6-10/group; 
bile n = 5/group; feces n = 4/group. Asterisks (*) represent statistically significant 
differences between CV and GF mice (p < 0.05) by Student’s t-test. CV - conventional 
mice, GF - germ-free mice, M - males. Dark blue and light blue bars represent CV and 
GF male mice, respectively. 
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Fig. 4.19. Representative chromatograms. UDCA was quantified using the LC-MS 
method developed in our laboratory to quantify bile acids. (A) Retention time of UDCA 
standard. (B) Control reaction mixture that does not have the BA substrate-CDCA 
added to the GF hepatic microsomal protein. (C) Reaction mixture containing GF 
hepatic microsomal protein + BA substrate CDCA. GF = germ-free. 
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Microsome 
sample 
AUC of 
CDCA 
AUC of 
UDCA 
UDCA formation efficiency (%) 
(AUC UDCA / AUC CDCA) x100 
CV M1 83214.5 29 0.035 
CV M2 74308.2 20.6 0.028 
  
CV 
Mean 0.031 
GF M1 138598.9 26.7 0.019 
GF M2 127108.7 28.8 0.023 
  
GF 
Mean 0.021 
 
Table 4.2. Comparison of the efficiency of UDCA formation by conventional (CV) 
and germ-free (GF) hepatic microsomal enzymes   
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Fig 4.20. Comparison of the efficiency of UDCA formation by conventional (CV) 
and germ-free (GF) hepatic microsomal enzymes. Reaction mixtures contained 
CDCA (200 µM); 0.5 mg of liver microsomal protein; 100 mM potassium phosphate 
buffer, pH 7.4; 2 mM NADPH in a final volume of 250 µL. After preincubation for 10 min 
at room temperature, reactions were initiated with NADPH and incubated for 60 min at 
37°C. Reactions were terminated by adding 1 mL of ice-cold acetonitrile, dried under 
vacuum and resuspended in 80 µL of 50% methanol. UDCA and CDCA were quantified 
using LC-MS. The efficiency of UDCA formation was reported as the ratio of the area 
under the curve (AUC) of the product BA (UDCA) formed to the AUC of the substrate 
BA (CDCA) used in the incubation mixture. 
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  UDCA formation efficiency, was calculated as the ratio of the area under the curve 
(AUC) of UDCA (product) formed to the AUC of CDCA (substrate) (Table 4.2). The 
results demonstrate that hepatic microsomes from CV mice had a UDCA formation 
efficiency of 0.03% and hepatic microsomes from GF mice had a UDCA formation 
efficiency of 0.02% (Fig. 4.20). This suggests that both GF and CV mice have a similar 
capacity to synthesize UDCA.  
 
III. Discussion 
The first report of quantification of BAs in GF mice was published in 1976, using 
crude analytical techniques (Eyssen et al., 1976). Last year, the second report of 
quantification of BAs in GF mice was published as we were finishing our studies. This 
recent publication described the BA composition in GF Swiss Webster mice (Sayin et 
al., 2013), whereas our studies were done with a widely used animal strain in BA 
research, the C57BL/6 mice in which the BA profiles in GF mice have not yet been 
characterized.  
In our study, I observed that GF mice have a longer intestinal tract and an 
enlarged cecum. The enlarged cecum phenotype can be considered to be a 
morphological marker for the absence of gut bacteria, as the cecum decreases to its 
normal size upon colonization of GF mice with gut bacteria (Schaedler et al., 1965). 
I also observed that gallbladders of GF mice are visually much larger and weigh 
about 4-5 fold more than gallbladders in CV mice. Bile flow is higher in GF mice 
compared to CV mice and this increase in bile flow might lead to the increase in 
gallbladder size. Enlarged gallbladders were also recently reported in GF Swiss 
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Webster mice (Sayin et al., 2013). BA activation of the TGR5 receptor in the gallbladder 
leads to an increase in gallbladder filling and gallbladder size (Li et al., 2011). So, I 
decided to determine whether BA–induced receptor TGR5 signaling is increased in GF 
mice. TGR5 activation will increased GLP-1 secretion from the enteroendocrine cells in 
the intestine, and increase expression of thyroid hormone activating enzyme (D2) and 
uncoupling protein (UCP3) in muscle and brown adipose tissue (Katsuma et al., 2005; 
Watanabe et al., 2006; Thomas et al., 2009). I observed an increase in the mRNA of 
PC1, which is the enzyme that cleaves the proglucagon peptide to make GLP-1, as well 
as a corresponding increase in serum GLP-1 and increase in the mRNA of the enzyme 
D2 in brown adipose tissue of GF mice. These observations suggest that increased 
concentrations and altered BA profiles in GF mice results in activation of TGR5 
signaling. This increased TGR5 signaling seen in GF mice is probably a major reason 
for the better glycemic control and resistance to obesity reported in GF mice (Backhed 
et al., 2007; Rabot et al., 2010). 
The BA profile of GF mice is strikingly different than that of CV mice. Compared 
to CV mice, GF male and female mice have increased total BAs in serum (4-fold), liver 
(2-fold), bile (2 to 3-fold), and ileal tissue (3 to 4-fold),  and decreased total BAs in feces 
(3-fold), indicating that the BA pool size is larger in GF mice compared to CV mice. The 
decrease in total BAs in the feces of GF mice suggests that there is increased 
reabsorption and recirculation of BAs, which is supported by the finding that the mRNA 
of Asbt, the ileal BA uptake transporter is also increased about 150% in GF mice. An 
earlier study performed in CV and GF rats used radioactive CA to determine the 
biological half-life of CA. The results showed that the half-life was about 2 days in CV 
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rats but 11 days in GF rats (Gustafsson et al., 1957). Although the half-life of CA is 
known to increase in germ-free rodents, the concentration of TCA or CA were not 
markedly increased in livers of GF mice, suggesting lower basal levels of CA synthesis 
in GF mice, which is in agreement with the decreased mRNA levels of Cyp8b1 
observed. 
  As expected, secondary BAs were essentially absent in all tissue compartments in 
GF mice. However, UDCA, which was thought to be a secondary BA in mice, was 
readily detected in tissues of GF mice suggesting that it could be a primary BA in mice. 
Biotransformation studies with liver microsomes isolated from both CV and GF mice 
verified that UDCA can be synthesized by metabolizing CDCA but not CA. Both GF and 
CV mouse livers appear to have a similar efficiency to convert CDCA to UDCA.  But the 
conversion is small, and the enzymatic reaction has not been fully characterized. 
Nonetheless, this is the first report that enzymes in mouse liver microsome preparations 
can synthesize UDCA from the primary BA CDCA  
Taurine-conjugated BAs increase and Tα+β MCA becomes the dominant BAs in 
all compartments analyzed in GF mice compared to CV mice. The increase in taurine-
conjugated BAs could be because bile salt hydrolase enzymes that deconjugate BAs 
present in gut bacteria are absent in GF mice. In addition, taurine-conjugation of BAs 
also decreases its hydrophobicity. As hydrophobic BAs cause tissue injury, this increase 
in taurine-conjugated BAs could be an adaptive response to elevated total BAs. 
Recently, TβMCA was identified to be an antagonist of the BA receptor FXR (Sayin et 
al., 2013). Increased levels of TβMCA in the intestine suppress intestinal FXR feedback 
regulation of BAs, and results in an increase in hepatic Cyp7a1 expression and activity 
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(Li et al., 2013; Sayin et al., 2013). However, my observations are not in line with this 
finding. In my study, although TβMCA levels increase in ileal tissue, there was not a 
decrease in the intestinal FXR pathway. Intestinal FXR inhibition should result in a 
decrease in ileal Fgf15 mRNA and hepatic SHP mRNA, as well as an increase in 
hepatic Cyp7a1 mRNA. But I observed no change in the mRNA of Fgf15, SHP and 
Cyp7a1 in GF and CV mice. Further, the mRNA of Cyp7a1 decreases in livers of female 
GF mice compared to CV mice.  
The mRNA of important enzymes involved in BA synthesis was quantified. The 
mRNA of the rate-limiting enzyme (Cyp7a1) are similar in livers of male GF and CV 
mice, even though there was an increase in total BAs in all tissues of the GF mice. The 
mRNA of Cyp8b1, the enzyme responsible for 12α-hydroxylation of BAs to make CA 
and the levels of CA are lower in GF mice compared to CV mice. The enzyme Cyp7b1 
is responsible for 7α-hydroxylation of cholesterol metabolites in the alternate pathway of 
BA synthesis, and the mRNA levels of Cyp7b1 are 30-50% lower in GF mice. This might 
result in a decreased BA output via the alternate pathway in GF mice 
As a result of increased total BAs in GF mice, one might predict that mRNA 
levels of genes involved in the FXR-mediated BA-feedback mechanisms would be 
activated. However, targets of FXR activation, such as SHP (in liver) and Fgf15 (in 
ileum) did not change. This suggests that both liver and ileal FXR receptor signaling are 
not different in GF compared to CV mice.  As mentioned above, TβMCA can antagonize 
ileal FXR and the markedly increased concentrations of Tα+β MCA found in ileum could 
indeed lead to inactivation of FXR, explaining why its target gene mRNAs were not 
altered.  
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The absence of gut bacteria leads to slower intestinal propulsion and increased 
intestinal transit time (Abrams and Bishop, 1967).  In the ileum, mRNA of the BA uptake 
transporter Asbt increased in GF male mice compared to CV mice. Therefore, the 
increased total BAs in tissues of GF mice could be due to increased reabsorption of 
BAs from the intestine, facilitated by the increased intestinal transit time and increased 
BA uptake by Asbt. Increased reabsorption of BAs in the intestine will result in 
increased enterohepatic circulation and increased half-life of BAs in GF rodents, as 
reported by others (Gustafsson et al., 1957).  Decreasing the number of gut bacteria by 
administration of antibiotics, results in increased ileal Asbt expression, decreased fecal 
BA excretion and increased hepatic BA concentration, similar to what we observe in GF 
mice (Hu et al., 2013). Further, Asbt-null mice that have limited enterohepatic circulation 
of BAs have increased fecal BA excretion and a decreased BA pool size, just the 
opposite of what is observed in GF mice (Dawson et al., 2003).  
Taken together, the BA profiles of both male and female GF mice are markedly 
altered compared to CV mice. GF mice have slower intestinal propulsion rates and 
increased BA reabsorption, which probably result in increased total BAs in all tissues 
analyzed. GF mice have increased proportions of MCAs, UDCA and taurine-conjugated 
BAs compared to CV mice. These BA changes render the BA pool more hydrophilic and 
the altered BA profile in GF mice results in the activation of TGR5 signaling which 
results in enlarged gallbladders, increased serum GLP-1 concentration and increased 
mRNA of thermogenesis related genes in brown adipose tissue and muscle. 
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CHAPTER 5 
ALTERATIONS IN THE EXPRESSION OF HEPATIC  
DRUG METABOLIZING ENZYMES IN GERM-FREE MICE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
I. Background 
  There are about 1014 bacteria that call the intestinal tract of each human their 
home. These bacteria grow and divide inside the gut lumen alongside ingested food, 
drugs, bile and GI secretions. To survive, gut bacteria have to metabolize food, bile, etc 
to extract energy from them. In general the host liver provides an ideal environment for 
oxidation and conjugation reactions, making polar and high-molecular-weight 
metabolites, whereas the gut bacteria provides an environment suited for reduction and 
hydrolysis reactions, making nonpolar and lower-molecular-weight metabolites (Sousa 
et al., 2008). These gut bacterial enzymes, metabolize drugs as well as some 
endobiotic substances, such as conjugated hormones, conjugated bilirubin and BAs.  
  Gut bacterial metabolism of orally administered drugs can alter their efficacy and 
clearance. For example, a prodrug such as sufasalazine on reduction by the bacteria in 
the colon, gives rise to 5-aminosalicylic acid (anti-inflammatory drug) and sulfapyridine 
(antibiotic) (Sousa et al., 2008). Liver is the major organ for drug metabolism. Phase-1 
drug metabolizing enzymes perform oxidation, hydrolysis, and reduction reactions on 
drugs and phase-2 drug metabolizing enzymes perform conjugation reactions. While the 
action of hepatic phase-1 and phase-2 enzymes generally make the drugs more 
hydrophilic, the enzymes of gut bacteria often make the drug more hydrophobic by 
deconjugating the conjugated drug metabolites, favoring intestinal uptake and 
increasing the half-life of drugs (Stojancevic et al., 2013).  
  In addition, gut bacteria can also alter the expression of hepatic drug 
metabolizing enzymes. Bacterial infections are known to down-regulate the expression 
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and activities of drug metabolizing enzymes such as the Cyps (Morgan, 1997). 
Endotoxin of common gram-negative bacteria, when injected into rats, can decrease 
hepatic drug metabolism and Cyp expression (Ueyama et al., 2005). Oral antibiotics, 
such as ciprofloxacin, can alter the metabolism of other drugs co-administered to the 
host (Xie et al., 2003). It was later noted that ciprofloxacin decreases the gut bacteria 
that make the secondary BA, LCA which decreases the activation of the nuclear 
receptor FXR and lowers Cyp expression in the liver (Toda et al., 2009b).  
 The drug metabolizing capacity of an individual varies not only because of 
polymorphisms in genes encoding host drug metabolizing enzymes, but probably also 
because of individual differences in gut bacterial species. Further, therapeutic 
modulation of gut bacteria by probiotics, prebiotics, and by fecal transplantation has the 
potential to alter the drug metabolizing capacity of the host and thus affect the 
pharmacokinetics and pharmacodynamics of orally administered drugs taken 
simultaneously by the host. Thus, there is a need to identify drug metabolizing enzymes 
that are altered by gut bacteria. The function of gut bacteria is best studied in a model 
system that lacks gut bacteria, such as GF mice. Very little is known about the hepatic 
drug metabolizing enzymes that are regulated by gut bacteria. The studies published so 
far, have only analyzed a small subset of hepatic drug metabolizing enzymes in GF 
mice and their results are contradictory (Bjorkholm et al., 2009; Toda et al., 2009c).  
 Therefore, the purpose of this study was to determine the alterations in hepatic 
drug metabolizing enzymes at the transcriptome level in GF mice as compared to CV 
mice. The hypothesis I tested is that absence of gut bacteria would alter drug 
metabolizing capacity of the host. This was accomplished by comparing the mRNA of 
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hepatic phase-1 and phase-2 drug metabolizing enzymes in the livers of GF and CV 
male mice using RNA-Seq. RNA-Seq provides a “true quantification” of transcripts and 
thus is an unbiased method of quantifying and comparing mRNA abundance of multiple 
genes (Cui et al., 2012). A physiological effect due to the differences in the levels of 
hepatic drug metabolizing enzymes was tested in intact animals by performing a 
pentobarbital sleeping test.  
II. RESULTS 
A. Alterations in mRNA expression of hepatic phase-1 drug metabolizing 
enzymes in GF mice compared to CV mice. 
Enzymes involved in phase-1 drug metabolism generally catalyze hydrolysis, 
reduction, and oxidation reactions. In the livers of GF mice, carboxylesterases and 
cytochrome P450s are the most altered hepatic phase-1 drug metabolizing enzymes 
compared to CV mice. 
Carboxylesterases (Ces). Ces are an important family of enzymes that 
hydrolyze drugs and other xenobiotics. The ester prodrug Cpt-11 (or irinotecan) is 
hydrolyzed to its active form SN-38 (an inhibitor of topoisomerase-1) by Ces. Ces1c and 
Ces3a are the Ces with the highest expression levels in the liver of mice.  
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Fig. 5.1. Gene expression of (A) Ces, (B) Akr and (C) Aldh. Total RNA was isolated 
from livers of adult male conventional (CV) and germ-free (GF) C57BL/6 mice (n = 3 per 
group). The cDNA libraries were sequenced 50bp paired-end using an Illumina 
HiSeq2000 sequencer. Approximately 80-100 million reads were generated per sample 
and over 95% of the reads were mapped to the mouse mm10 genome (Tophat). The 
transcript abundance was estimated by Cufflinks, and differential expression was 
determined using Cuffdiff (FDR-BH<0.05). Ces- Carboxylesterase, AKR- Aldo-keto 
reducatase, Aldh-Aldehyde dehydrogenase, FPKM- fragments per kilobase of exon per 
million reads mapped. 
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Compared to CV mice, GF mice have decreased levels of Ces2a (39%), Ces3b 
(23%), and Ces4a (40%) mRNA, and increased levels of Ces1g mRNA (42%). The 
mRNAs of other Ces (10 out of 14) were similar in the livers of CV and GF mice (Fig. 
5.1.A). 
Aldo-keto reductase (Akr): Akrs are NADPH-dependent oxido-reductase 
enzymes, which reduce aldehydes to alcohols. Akr1c6 is the highest expressed Akr in 
the livers of CV mice. GF mice have increased mRNA levels of Akr1c20 (30%) and 
Akr1d1 (56%), and decreased levels of Akr1c19 mRNA (31%) in liver, compared to CV 
mice. The mRNAs of the other Akrs (6 out of 9) were quantitatively similar in the livers 
of both groups of mice (Fig.5.1.B).  
Aldehyde dehydrogenase (Aldh). Aldh enzymes catalyze the oxidation of 
aldehydes to carboxylic acids using NAD+ as a cofactor. Aldh1a1 and Aldh2 are the 
most highly expressed Aldh in the livers of mice. Aldh3a2 mRNA is increased (54%) 
and Aldh1b1 mRNA is decreased (29%) in livers of GF mice compared to CV mice. The 
mRNAs of other Aldhs (9 out of 11) expressed in liver were similar in CV and GF mice 
(Fig. 5.1.C). 
Epoxide hydrolase (Ephx), Quinone reductase (Nqo), and Carbonyl 
reductase (Cbr). The mRNA levels of different Ephxs, Nqos, and Cbrs were similar in 
livers of GF and CV mice (Fig. 5.2.A, B and C).  
Aldehyde oxidase (Aox). Aox is an important class of cytosolic drug 
metabolizing enzyme with broad substrate specificity in the liver. Aox3 is the highest 
expressed AOX in the livers of mice, and its mRNA levels are similar in the livers of CV 
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Fig. 5.2. Gene expression of (A) Eph, (B) Nqo, (C) Cbr, (D) Aox, and (E) Fmo. Total 
RNA was isolated from livers of adult male conventional (CV) and germ-free (GF) 
C57BL/6 mice (n = 3 per group). The cDNA libraries were sequenced 50bp paired-end 
using an Illumina HiSeq2000 sequencer. Approximately 80-100 million reads were 
generated per sample and over 95% of the reads were mapped to the mouse mm10 
genome (Tophat). The transcript abundance was estimated by Cufflinks, and differential 
expression was determined using Cuffdiff (FDR-BH<0.05). Eph- Epoxide hydrolase, 
Nqo- Quinone reductase, Cbr- Carbonyl reductase, Aox- Aldehyde oxidase, Fmo- Flavin 
monooxygenase, FPKM- fragments per kilobase of exon per million reads mapped. 
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and GF mice. Compared to CV mice Aox1 mRNA levels are reduced by about one-third 
in GF mice (Fig. 5.2.D). Aox1 plays a role in ethanol-induced liver injury (Shaw and 
Jayatilleke, 1990) 
Flavin monooxygenases (Fmo). Fmo are a FAD-containing monooxygenases 
that require NADPH to oxidize nucleophilic nitrogen, sulfur, and phosphorous atoms of a 
xenobiotic. Fmo1 and Fmo5 are the two most highly expressed Fmos in livers of mice. 
GF mice have increased Fmo2 (39%) and Fmo5 (38%) mRNA in the liver compared to 
CV mice, whereas the mRNA levels of Fmo1 and 4 are similar in livers of GF and CV 
mice (Fig.5.2.E).  
NADPH-cytochrome P450 oxidoreductase (POR). POR is essential in passing 
electrons from NADPH to Cyps located in the endoplasmic reticulum. There exists only 
one POR for the many Cyp enzymes in the liver, and GF mice have increased POR 
mRNA levels (46%) compared to CV mice (Fig. 5.3.A). This may lead to an overall 
increase in Cyp activity. 
Cytochrome P450 enzyme (Cyps).  Cyps are the largest family of drug 
metabolizing enzymes in the liver and are responsible for the majority of hepatic phase-
1 drug metabolism. Cyps are heme-containing enzymes that catalyze the 
monooxygenation of xenobiotics. Cyps are divided into families and subfamilies based 
on amino acid homology. The first three families, namely Cyp1, Cyp2, and Cyp3, are 
involved in xenobiotic metabolism. Although, the Cyp4 family is important for ω-
hydroxylation of fatty acids and prostaglandins, its members also play a role in 
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xenobiotic metabolism (Hsu et al., 2007). Therefore, the expression of Cyp1, Cyp2, 
Cyp3, and Cyp4 families in livers of CV and GF mice are described below.  
a) Cyp1 family- GF mice have increased Cyp1a2 mRNA levels (51%) in liver 
compared to CV mice (Fig. 5.3.A). 
b) Cyp2a subfamily- Among the Cyp2a subfamily, Cyp2a5 was highly expressed in 
the livers of mice, and GF mice have increased Cyp2a5 (143%) and Cyp2a22 
mRNA levels (33%) in livers compared to CV mice. Cyp2a5 is an Ahr target gene 
and is responsible for the metabolism of drugs and xenobiotics such as 
halothane, nicotine, and aflatoxin B1. The mRNA levels of Cyp2a12 and Cyp2a4 
are similar (2 of 6) in the livers of CV and GF mice (Fig. 5.3.A). 
c) Cyp2b subfamily- Cyp2b subfamily is expressed at low levels in livers of mice. 
In the livers of GF mice, the mRNA of Cyp2b9 was higher (7454%) but Cyp2b10 
mRNA was lower (57%) lower than livers of CV mice (Fig. 5.3.A). 
d) Cyp2c subfamily- Cyp2c29 is the highest expressed among the Cyp2c 
subfamily members in livers of mice. GF mice have higher mRNA levels of the 
following Cyp2c subfamily members compared to CV mice livers: Cyp2c38, 
Cyp2c39, Cyp2c40, Cyp2c50, Cyp2c54, Cyp2c67, Cyp2c68, and Cyp2c69. The 
mRNA of Cyp2c55 was decreased and the mRNA levels of Cyp2c29, Cyp2c37, 
Cyp2c44, and Cyp2c70 are similar in the livers of CV and GF mice (Fig. 5.3.B).  
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Fig.  5.3. Gene expression of (A) Por, Cyp1a, 2a and 2b subfamily, (B) Cyp2c 
subfamily, and (C) Cyp2d subfamily. Total RNA was isolated from livers of adult male 
conventional (CV) and germ-free (GF) C57BL/6 mice (n = 3 per group). The cDNA 
libraries were sequenced 50bp paired-end using an Illumina HiSeq2000 sequencer. 
Approximately 80-100 million reads were generated per sample and over 95% of the 
reads were mapped to the mouse mm10 genome (Tophat). The transcript abundance 
was estimated by Cufflinks, and differential expression was determined using Cuffdiff 
(FDR-BH<0.05). POR- NADPH-cytochrome P450 oxidoreductase, Cyp- Cytochrome 
P450, FPKM- fragments per kilobase of exon per million reads mapped. 
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Fig.  5.4. Gene expression of (A) Cyp2e, 2f, and 3a subfamily and (B) Cyp4 family. 
Total RNA was isolated from livers of adult male conventional (CV) and germ-free (GF) 
C57BL/6 mice (n = 3 per group). The cDNA libraries were sequenced 50bp paired-end 
using an Illumina HiSeq2000 sequencer. Approximately 80-100 million reads were 
generated per sample and over 95% of the reads were mapped to the mouse mm10 
genome (Tophat). The transcript abundance was estimated by Cufflinks, and differential 
expression was determined using Cuffdiff (FDR-BH<0.05). Cyp- Cytochrome P450, 
FPKM- fragments per kilobase of exon per million reads mapped. 
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e) Cyp2d subfamily- Among the Cyp2d subfamily members, Cyp2d9 is the most 
highly expressed. GF mice have increased Cyp2d13, and Cyp2d37-ps mRNA in 
the livers compared to CV mice. All other mRNA levels of other eight Cyp2d 
subfamily members are similar in the livers of CV and GF mice (Fig. 5.3.C). 
f) Cyp2e and Cyp2f subfamiles- Cyp2e1 and Cyp2f2 are both highly expressed 
Cyps in the livers of CV mice and their mRNA levels were similar in GF and CV 
mice (Fig. 5.4.A).  
g) Cyp3a subfamily- Cyp3a11 is the highest expressed member among the Cyp3a 
subfamily in livers of CV mice and it is the most decreased mRNA in livers of GF 
mice (87%) compared to CV mice. GF mice also have reduced mRNA levels of 
Cyp3a16 (86%), Cyp3a44 (87%), and Cyp3a59 (11%). The mRNA levels of 
Cyp3a13, Cyp3a25, and Cyp3a41a are similar in livers of CV and GF mice (Fig. 
5.4.A). 
h)  Cyp4a, 4b, 4f, and 4v subfamilies- In livers of GF mice, the mRNA of 
Cyp4a10, and Cyp4a14, Cyp4a31, and Cyp4a32 are increased between 150-
200%, whereas mRNA of Cyp4a12b, was increased 31% over CV mice. Cyp4f17 
mRNA is decreased (38%) in GF mice, and the mRNA levels of Cyp4a12a, 
Cyp4b1, Cyp4f13, Cyp4f14, Cyp4f15, and Cyp4v3 are similar in livers of CV and 
GF mice (Fig. 5.4.B). 
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Fig.5.5. Gene expression of Gsts (A), (B) and Ugts (C). Total RNA was isolated from 
livers of adult male conventional (CV) and germ-free (GF) C57BL/6 mice (n = 3 per 
group). The cDNA libraries were sequenced 50bp paired-end using an Illumina 
HiSeq2000 sequencer. Approximately 80-100 million reads were generated per sample 
and over 95% of the reads were mapped to the mouse mm10 genome (Tophat). The 
transcript abundance was estimated by Cufflinks, and differential expression was 
determined using Cuffdiff (FDR-BH<0.05). Gst- Glutathione transferase, Ugt- uridine 
diphosphate-glucuronosyltransferase, FPKM- fragments per kilobase of exon per million 
reads mapped. 
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B. Alterations in mRNA expression of hepatic phase-2 drug metabolizing 
enzymes in GF mice compared to CV mice. 
Phase-2 drug metabolizing enzymes are involved in conjugation reactions. Gut 
bacteria possess enzymes that can deconjugate conjugated xeno- and endobiotics. The 
glutathione transferases and UDP-glucuronosyltransferases are the most altered phase-
2 drug metabolizing enzymes in livers of GF mice compared to CV mice. 
  Glutathione transferase (Gst). Gst enzymes catalyze the transfer of glutathione 
to the xenobiotic to make it more hydrophilic. Gsts detoxify polycyclic aromatic 
hydrocarbons and other carcinogens in the diet and tobacco and therefore 
polymorphisms in Gsts are associated with differences in the susceptibility to 
carcinogens. Among Gst family members, the highest expressed Gsts in livers of mice 
include, Gstp1. GF mice have decreased mRNA of Gsta1 (48%), Gstp1 (66%), Gstp2 
(64%), and Gstm3 (32%) compared to CV mice. The gene expression of Gstp1 was the 
second most decreased among the phase-1 and Phase-2 genes in livers of GF mice. 
Gut bacterial metabolites, the short chain fatty acids, are known to induce the 
expression of Gstp1 in intestine (Stein et al., 1996), and it appears that they might also 
increase Gstp1 expression in liver. The mRNA levels of Gstt2 (67%) and Gstt3 (67%) 
are increased in livers of GF mice compared to CV mice. Other Gsts have similar 
expression levels in livers of CV and GF mice. The enzyme glutamate-cysteine ligase 
catalytic subunit (Gclc) is the rate limiting enzyme for glutathione synthesis. Gclc mRNA 
levels were also decreased (40%) in livers of GF mice compared to CV mice (Fig. 5.5.A 
and B). 
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  UDP-glucuronosyltransferase (Ugt). Ugts are enzymes that catalyze the 
transfer of glucuronic acid from the co-substrates uridine diphosphate glucuronic acid to 
the xenobiotic. Among the Ugts, Ugt2b5, Ugt2b36, and Ugt2b1 are the highest 
expressed in livers of mice. Livers of GF mice have decreased Ugt2b35 (32%), Ugt2b37 
(10%), and Ugt2b38 (11%) mRNA compared to CV mice. The mRNA levels of other 
Ugts are similar in the livers of CV and GF mice (Fig. 5.5.C). 
  Sulfotransferase (Sult). Sults catalyze the transfer of a sulfonic acid group from 
the co-substrate PAPS (3’-phosphoadenosine-5’-phosphosulfate) to the xenobiotic. 
Sult1a1 is the highest expressed Sult in the livers of mice. GF mice have increased 
Sult1a1 (52%), Sult1b2 (70%) and Sult1d1 (68%) mRNA levels compared to CV mice, 
wheras the mRNA of Sult5a1 is decreased (48%) (Fig. 5.6.A). 
  N-acetyl transferase (Nat). The Nat enzymes catalyze the transfer of an acetyl 
group from the cofactor acetyl-coenzyme A to an amino group in the xenobiotics. This 
conjugation makes the xenobiotic less water-soluble unlike other phase-2 drug 
metabolizing reactions that make them more water soluble. Nat6 is the highest 
expressed Nat enzyme in the livers of mice. The mRNAs of all Nat enzymes are similar 
in livers of GF and CV mice (Fig. 5.6.B).  
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Fig.  5.6. Gene expression of (A) Sults, (B) Nats, (C) transcription factors in liver. 
Total RNA was isolated from livers of adult male conventional (CV) and germ-free (GF) 
C57BL/6 mice (n = 3 per group). The cDNA libraries were sequenced 50bp paired-end 
using an Illumina HiSeq2000 sequencer. Approximately 80-100 million reads were 
generated per sample and over 95% of the reads were mapped to the mouse mm10 
genome (Tophat). The transcript abundance was estimated by Cufflinks, and differential 
expression was determined using Cuffdiff (FDR-BH<0.05). Sults- Sulfotransferases, 
Nats- N-acetyl transferase, Ahr- Aryl hydrocarbon receptor, CAR- Constitutive 
androstane receptor, PXR- Pregnane X receptor, PPARα- Peroxisome proliferator-
activated receptor α, Nrf2- nuclear factor erythroid 2-related factor 2, FPKM- fragments 
per kilobase of exon per million reads mapped. 
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Fig 5.7. Protein expression of Cyp2b10 and Cyp3a11 in (A) Males and (B) 
Females. Western blot results of Cyp2b10 and Cyp3a11 in the livers of GF and CV 
mice. Intensities of protein bands were quantified using Image J software.  Asterisks (*) 
represent statistically significant differences between CV and GF mice (p < 0.05) by 
Student’s t-test. Dark blue and light blue bars represent CV and GF male mice; red and 
pink bars represent CV and GF female mice, respectively. CV- conventional mice. GF- 
germ-free mice. M- males. F- females.   
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Fig 5.8 Pentobarbital induced anesthesia. Pentobarbital (40 mg/kg) was injected 
intraperitoneally and the time between loosing and subsequently regaining the righting 
reflex is plotted in the graph as minutes. Data is represented as mean ± SEM, n = 4, 
female mice per group. CV refers to conventional mice, GF refers to germ-free mice. F 
refers to females. 
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C. Alterations in mRNA expression of transcription factors in the liver 
Hepatic transcription factors such as, Ahr, CAR, PXR, PPARα, and Nrf2 act as 
xenosensors and regulate the expression of hepatic drug metabolizing enzymes. 
Interestingly, GF mice have higher Ahr, CAR, PPARα, and Nrf2 mRNA in liver than CV 
mice. The mRNA of PXR remains the same in the livers of GF and CV mice (Fig. 5.6.C). 
D. Alterations in protein levels of Cyp enzymes 
The mRNA of the two very important drug metabolizing enzymes, Cyp2b10 and 
Cyp3a11 were decreased in livers of GF mice compared to CV mice. Therefore, I 
quantified the protein levels of Cyp3a11 and Cyp2b10 in the livers of CV and GF mice. 
Similar to their mRNA, both Cyp2b10 and Cyp3a11 protein levels were decreased in 
livers of GF mice compared to CV mice (Fig. 5.7). 
E. Pentobarbital sleeping test 
Next I wanted to determine whether differences in mRNA and protein levels of 
Cyp2b10 and Cyp3a11 resulted in a physiological effect in the GF mice. The 
pentobarbital sleeping test is an index of hepatic drug metabolism in intact animals. The 
time between losing and regaining the righting reflex after administration of the 
anesthetic pentobarbital is an indication of how quickly the pentobarbital is metabolized. 
The GF mice slept for 60 minutes whereas CV mice slept for only 45 minutes. Thus GF 
mice slept 33% longer when administered the same dose of pentobarbital 
intraperitoneally than CV mice (Fig.5.8), suggesting that pentobarbital is metabolized 
slower in GF mice compared to CV mice.  
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III. Discussion 
Liver is the major organ for drug metabolism. Moreover, it is known that, 
antibiotics can alter gut bacteria and decrease the expression of some drug 
metabolizing enzymes in the liver. However, previous studies, only analyzed a small 
subgroup of host hepatic drug metabolizing enzymes.  Therefore, I analyzed the hepatic 
transcriptome of the GF and CV mice by RNA-Seq and compared the mRNA levels of 
phase-1 and phase-2 drug metabolizing enzymes in GF and CV mice. The absence of 
gut bacteria in mice alters the gene expression of a number of phase-1 and phase-2 
drug metabolizing enzymes.  
Two groups have earlier performed microarray analysis and described changes 
in the mRNA of hepatic drug metabolizing enzymes in GF NRMI and IQI mice 
(Bjorkholm et al., 2009; Toda et al., 2009c). Their results are contradictory to each other 
and our observations are different from both of their reports, possibly due to differences 
in the strains of mice used in the study.  
Table 5.1 shows the list of hepatic drug metabolizing genes that were altered in 
GF mice compared to CV mice in our study compared to the two previous microarray 
studies on GF mice.  In my study, the mRNA levels of Cyp2b9 increased markedly 
(7454%) whereas in the study by Toda et al., the mRNA levels of Cyp2b9 decreased in 
GF mice compared to controls (Toda et al., 2009c). The mRNA levels of Sult1c2 and 
Ugt1a1 increase in GF mice in the study by Bjorkholm et al., whereas the mRNA levels 
were the same in GF and CV mice in my study (Bjorkholm et al., 2009). The gene 
expression of major xenobiotic-sensing nuclear receptors PXR remained the same in 
the livers of GF and CV mice in my study, whereas Toda et al. reported a decrease in 
156 
 
PXR mRNA in GF mice (Toda et al., 2009c). The gene expression of other xenobiotic-
sensing nuclear receptors Ahr and CAR increase in livers of GF mice compared to CV 
mice in my study. Toda et al. hypothesize that in GF IQI mice, the decreased 
concentrations of secondary BAs is the reason for the decrease in gene expression of 
the nuclear receptor CAR and its target genes (Toda et al., 2009c). Although, Bjorkholm 
et al. explain that in GF NRMI mice, the mRNA of the nuclear receptor CAR and its 
target genes increase (Bjorkholm et al., 2009) I do not see an increase in all CAR target 
genes. In my study, the mRNA of the CAR target gene, Cyp2b9 increases, whereas 
Cyp2a4 mRNA remains the same and Cyp2b10 mRNA decreases in the livers of GF 
mice compared to CV mice. 
  Pentobarbital treated GF mice tended to sleep longer than CV mice, suggesting 
that metabolism of pentobarbital is slower in GF mice than CV mice, and this agrees 
with the observation that Cyp2b10 and Cyp3a11 mRNA and protein are lower in GF 
mice than CV mice.  
This study provides a list of drug metabolizing enzymes whose mRNA levels 
increase or decrease in the absence of gut bacteria (Table 5.2). These genes can be 
referred to as “gut bacteria target drug metabolizing genes” in the liver of mice as their 
levels are altered by gut bacteria.  
The drug metabolizing enzymes whose mRNA decrease in GF mice are probably 
increased normally in the presence of gut bacteria to help metabolize gut bacterial 
metabolites. Therefore, the drug metabolizing enzymes whose mRNA increase in GF 
mice are probably enzymes whose functions are performed by the gut bacterial 
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enzymes and therefore in the absence of gut bacteria they have to be induced to 
compensate for the  change.  
In conclusion, there are a number of hepatic drug metabolizing enzymes that are 
target genes for gut bacteria, including the major drug metabolizing enzyme Cyp3a11. 
These changes may alter the pharmacokinetics and pharmacodynamics of orally 
administered drugs. The composition of gut bacteria may one day be used to predict a 
person’s response to a drug. It will be important to study the effect of probiotic strains of 
bacteria on drug metabolizing genes to prevent potential detrimental interactions with a 
simultaneously ingested drug. Altering gut bacteria might provide a novel approach to 
modify the drug metabolizing capacity of the liver. 
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Table 5.1 Comparision of  gene expression of drug processing genes in different 
strains of GF mice compared to their respective CV mice 
 
 
 
 Gene Expression In GF mice compared to CV mice (approx.) 
Gene name 
GF IQI mice 
(Toda et al) 
GF NRMI mice 
(Bjorkholm et al) 
GF C57BL6 mice 
(this study) 
Cyp1a2 50% decrease  51% increase 
Cyp2a4 86% decrease 340% increase No change 
Cyp2b9 99% decrease 2325% increase 7457% increase 
Cyp2b10   57% decrease 
Cyp2c38  140% increase 74% increase 
Cyp3a11 90% decrease  87% decrease 
Cyp3a13 50% decrease  No change 
Cyp3a16 100% decrease  86% decrease 
Cyp3a25 20% decrease  No change 
Cyp3a41 99% decrease  No change 
Cyp3a44 98% decrease  87% decrease 
Sult1b1  75% increase 70% increase 
Sult1c2  80% increase No change 
Sult1d1 75% decrease 95% increase 68% increase 
Gstt3  100% increase 67% increase 
Gstp1  110% decrease 66% decrease 
Ugt1a1  75% increase No change 
Ahr 52% decrease  50% increase 
CAR 80% decrease 100% increase 50% increase 
PXR 33% decrease  No change 
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Table 5.2  List of genes that are differentially regulated at the transcription level 
by the presence of gut bacteria. 
  
Genes expression changes in GF mice compared to CV 
mice 
  Decreased in GF mice Increased in GF mice 
  
 
Ces2a Ces1g 
  Ces3b Akr1c20 
  Ces4a Akr1d1 
Phase-1 drug 
metabolizing 
enzymes 
Akr1c19 Aldh3a2 
Aldh1b1 Fmo2,5 
Aox1 Cyp1a2 
  Cyp2b10 Cyp2a5,22 
  Cyp3a11,16,44,59 Cyp2b9 
  Cyp4f17 Cyp2c38,39,40,50,54,67,68,69 
    
Cyp4a10,12b,14,31,32 
 
  Decreased in GF mice Increased in GF mice 
  
 
Gsta1 Gstt2,3 
Phase-2 drug 
metabolizing 
enzymes 
Gstp1,2  Sult1a1 
Gstm3 Sult1b1 
Ugt2b35,37,38 Sult1d1 
  Sult5a1   
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CHAPTER 6 
 DISCUSSION OF DISSERTATION 
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6.1 Summary and Discussion 
Planet earth is not a sterile place, thus all animals that live on earth have 
microorganisms living on and in them. This must be beneficial for both the animals and 
the microorganisms as this symbiotic relationship has been selected by nature. Human 
beings have about 20,000 genes in their genome, but serve as a host to a variety of 
microorganisms that have about 5-8 million genes in total. The intestinal bacteria 
interact with the host and thereby, regulate many biochemical processes in the host 
such as BA and drug metabolism. Gut bacteria vary significantly between individuals 
and therefore, may be responsible for inter-individual differences in BA concentrations 
and drug responses. Further, alterations of gut bacteria in diseases or by therapeutic 
modulation of gut bacteria have the potential to alter host BA signaling and drug 
responsiveness. Thus, the overall goal of this dissertation was to expand the 
understanding of the role of gut bacteria in regulating host bile acid homeostasis and 
hepatic drug metabolism. 
Gene-knockout mice are excellent models to understand the function of a gene. 
Similarly, mice that do not have gut bacteria (GF mice) provide an excellent animal 
model to understand the function of gut bacteria. Learning how BA profiles and 
expression of hepatic drug metabolizing enzymes change in GF mice compared to 
conventional mice, will reveal the regulatory role of gut bacteria in host BA composition, 
drug metabolism, physiological homeostasis as well as protection against pathological 
disorders. 
Therefore, in Specific Aim 1, differences in the BA profile, concentration, and BA 
signaling in GF mice were compared to CV mice. The BA profile was markedly different 
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in GF mice compared to CV mice. GF mice have only a few types of BAs (only primary 
BAs), which suggests that gut bacteria produce differences in the BA profile. It is known 
that BAs are not equal in their capacity to activate BA receptors, but the role of 
individual BAs are not yet known. In the absence of gut bacteria, several BAs are 
missing from circulation, and therefore their functions will be lost. Antibiotic 
administration might also have the same effect of reducing the BA variety from the BA 
pool. Therefore, it is very important to discern the function of individual BAs.  
GF mice have increased total BAs in all tissue compartments examined, 
demonstrating that gut bacteria regulate the BA composition and BA pool size which in 
turn might affect cholesterol homeostasis in the host. TβMCA was identified as an FXR 
antagonist that is able to increase BAs by decreasing the feedback mechanism (Sayin 
et al., 2013). However, in our study, although TβMCA is increased in the ileal tissue, 
there is no decrease in the mRNA levels of FXR target genes (Fgf15 and SHP), and no 
increase in Cyp7a1.The reason for this difference is not known, but I suspect there 
could be a strain difference, since the previous study by Sayin et al. (Sayin et al., 2013) 
used Swiss webster mice and we used C57BL/6.  
The increase in total BAs in all tissue compartments of GF mice is probably at 
least in part due to an increase in the reabsorption of BAs by the ileal BA uptake 
transporter (Asbt). GF mice also have decreased gut motility, and thus BAs remain in 
the intestine longer favoring more BAs to enter the enterohepatic circulation. This would 
also explain the increased half-life of CA in GF rats reported by others (Gustafsson et 
al., 1957). Furthermore, taurine conjugation lowers the pKa of BAs and increasing their 
water solubility. The increased concentrations of MCA and UDCA as well as the 
163 
 
increased total taurine conjugated BAs in GF mice makes the GF BA pool more 
hydrophilic compared to CV mice. This is probably an adaptive response to the 
increased total BAs, as hydrophobic BAs are known to cause tissue damage.  
UDCA, which was thought to be a secondary BA made by gut bacteria, increased 
in GF mice tissues. This suggested that UDCA is a primary BA in mice. In vitro 
experiments confirmed that UDCA indeed can be synthesized from CDCA by enzymes 
in mouse liver microsomes. It is important to know the basic biology of UDCA as it is 
used as an oral drug to dissolve cholesterol gallstones and treat liver diseases. 
Increased concentrations of UDCA in bile, prevents cholesterol gallstone formation in 
obese patients who lose weight rapidly (Broomfield et al., 1988).  
Although I did not observe alterations in FXR signaling in GF mice, I did 
demonstrate an increase in TGR5 signaling. TGR5 activation is known to increase 
gallbladder size, increase GLP-1 secretion, and increase thermogenesis in brown 
adipose tissue and muscle. In the present study, GF mice displayed increased 
gallbladder size, increased GLP-1 in serum, and increased mRNA of the enzyme type 2 
iodothyronine deiodinase (D2), which increases energy expenditure as heat in brown 
adipose tissue. This increase in TGR5 signaling could be a reason for the resistance to 
diet-induced obesity reported in GF mice (Backhed et al., 2007; Rabot et al., 2010). 
These alterations in BA composition, BA concentration, and BA signaling in the 
absence of gut bacteria raise several questions, such as, what are the differences in the 
BA profile and signaling in dysbiosis-associated illnesses, such as obesity and 
inflammatory bowel disorder, and do probiotic bacteria alter BA profiles and signaling.  
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The altered BA profile in GF mice might point to a BA that is a potent TGR5 
agonist and that treating with that TGR5 agonist BA could be used to increase TGR5 
signaling and increase serum GLP-1 concentration. This might be a good alternative to 
GLP-1 analogs (eg. liraglutide) and DPP-4 inhibitors (eg. sitagliptin) to treat type-2 
diabetes and metabolic disorders. Along the same line, a recent study demonstrated 
oral administration of the antioxidant tempol to mice decreases Lactobacillus species in 
their gut leading to accumulation of TβMCA, inhibition of FXR signaling and resistance 
to obesity (Li et al., 2013). Although humans do not make TβMCA, studies like these 
might lead to the establishment of TβMCA as a therapeutic drug.  
Specific aim 2 determined the alterations in mRNAs of drug metabolizing 
enzymes in livers of GF mice by RNA-Seq. A number of hepatic phase-1 and phase-2 
genes were altered in the absence of gut bacteria.  Table 5.2 provides the list of genes 
that were altered in GF mice compared to CV mice. Because these genes are altered 
by the absence of gut bacteria, they can be called “gut bacteria target genes”. This is 
important for two reasons. First, the use of antibiotics, probiotics, or prebiotics may alter 
the drug metabolizing capacity of the host and thus alter the action and disposition of 
orally ingested drugs when taken simultaneously. Second, differences in the 
composition of gut bacteria can lead to variations in the expression of some drug 
metabolizing enzymes in the liver and this can lead to inter-individual variations in drug 
response and drug metabolism. 
Human CYP3A4 metabolizes more than 60% of all drugs. The mRNA of 
Cyp3a11, the mouse homolog of CYP3A4, decreased 87% in livers of GF C57BL/6 
mice compared to CV mice. This suggests that intestinal bacteria play an important role 
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in regulating this critical drug metabolizing enzyme. The fact that in the pentobarbital 
sleeping test, GF mice slept longer than CV mice confirmed that the marked changes in 
the mRNA levels of Cyp3a11 also has consequences at the enzyme activity level which 
might not be the case for other enzymes where the changes at the mRNA level were 
smaller. Follow-up experiments investigating the respective enzyme activities and their 
protein expression levels are needed to clarify this.  
Expression levels of several genes decreased in GF mice and it is likely that 
these genes are involved in metabolizing gut bacterial metabolites and therefore their 
expression should be higher in the presence of gut bacteria. An example of this is a 
study that demonstrated that short chain fatty acids can increase the expression of drug 
metabolizing enzymes in human primary colon cancer cells (Sauer et al., 2007).  
Another possibility is that in the presence of gut bacteria the liver upregulates 
some enzymes such as Ugts, to conjugate drugs and other xeno- and endobiotics to 
help in their elimination. Subsequently, the conjugated drugs will become deconjugated 
by the gut bacterial enzymes, such as β-glucuronidases, and the unconjugated drug will 
enter the enterohepatic circulation to be conjugated by the liver enzymes again.  
Therefore, in the absence of gut bacteria, these hepatic enzymes are downregulated. 
Several genes showed increased expression in GF mice compared to CV mice. 
The functions of these enzymes might also be performed by gut bacterial enzymes, and 
therefore, in the presence of gut bacteria these enzymes would be downregulated while 
they would be increased in the absence of gut bacteria.  
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Overall, our findings provide additional insights into factors affecting drug 
metabolism and ways to alter drug metabolism by modulating the number and 
composition of intestinal bacteria. 
 
6.2  Limitations 
a) The major goal of the study described in Chapter 4 was to compare the BA 
composition and concentration in various tissues of GF C57BL/6 mice compared to CV 
mice. Although this goal was achieved, BA pool size cannot be calculated from this 
study because BA concentration of the intestinal contents was not quantified.  
 
b) The biotransformation studies carried out demonstrate that hepatic 
microsomes can synthesize UDCA from a primary BA, CDCA. The specific enzymes 
involved in the reaction have not yet been identified.  
 
c) There is evidence suggesting that TGR5 receptor is constitutively activated in 
GF mice. However, rederivation of TGR5-null mice as GF mice will demonstrate 
whether these changes seen in GF mice are only due to TGR5 activation. 
 
d) Although GF mice are a unique and useful animal model in evaluating the 
function of gut bacteria, being germ-free creates fundamental differences in the 
physiology of the animal that cannot be overlooked. For example, GF mice have an 
overactive immune system (Olszak et al., 2012) and this could indirectly influence the 
expression of genes in liver. 
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e) Further proof that all the changes seen in GF mice are indeed due to the 
absence of gut bacteria comes when the changes in GF mice are reversed to some 
extent upon colonization of the GF mice. 
In conclusion, this dissertation work has provided the first step towards a detailed 
roadmap describing the alterations in BA composition, BA signaling, and expression of 
hepatic drug metabolizing enzymes in GF C57BL/6 mice compared to CV mice. 
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CHAPTER 7 
FUTURE STUDIES 
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7.1 BAs and gut bacteria 
This dissertation raises important and exciting possibilities of extensive evaluation of 
the role of gut flora in altering BA profiles thereby promoting health and alleviating 
metabolic syndrome related pathologies. A few examples of interesting future studies 
are given below. 
a) Colonize GF mice with intestinal bacteria from conventional mice for different 
time periods and monitor the microbial composition in the intestine and BA profile 
in the various BA enterohepatic compartments over that time period. This will 
provide information about which bacterial population(s) are important for the 
reappearance of secondary BAs.  The GF mice can also be colonized with 
human intestinal bacteria to generate a humanized microbiome mouse model 
(Martin et al., 2008; Turnbaugh et al., 2009; Kashyap et al., 2013).  
b) Several probiotic strains of bacteria on the market are known to possess 
enzymes to metabolize BAs (Tannock et al., 1989; Begley et al., 2006; Ruiz et 
al., 2013). It would be interesting to colonize GF and CV C57BL/6 mice and study 
changes in the BA profile that these probiotic bacteria produce in the presence 
and absence of other bacteria in the intestine. Most of the probiotic preparations 
possess bile salt hydrolase, the enzyme required for deconjugating BAs. This 
would result in a decrease in taurine conjugated BAs and potentially in an 
increase in ileal FXR signaling. 
c)  The changes in the BA profile and BA signaling in GF mice compared to CV 
mice could also be the result of the absence of secondary BAs. Therefore, an 
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interesting experiment would be to study the effects of that secondary BA feeding 
will have on the BA profile and BA signaling in GF mice.      
7.2 Biosynthesis of UDCA 
The observations in this dissertation and previous studies in our laboratory 
suggest that UDCA is synthesized from CDCA (Zhang and Klaassen, 2010; Song et al., 
2011). CDCA biotransformation reactions with specific enzyme inhibitors and inhibitory 
antibodies would allow to at least narrow down which enzymes are involved. 
7.3 T-MCA AND T-UDCA as TGR5 agonists 
The increase in the concentration of taurine-conjugated MCA and UDCA 
correlate with the marked increase in serum GLP1 in GF C57BL/6 mice compared to 
CV mice. It has been shown that the secondary BAs, DCA and LCA can activate TGR5, 
which results in secretion of GLP-1 in STC-1 cells (Katsuma et al., 2005). Similar 
studies need to be conducted with taurine conjugated MCA and UDCA to determine 
their potency to activate TGR5 signaling.  
7.4 Hepatic drug metabolizing enzymes and gut bacteria 
The results of Specific aim 2 provide a list of genes, whose gene expression is 
altered in the absence of gut bacteria.  It has been recognized that antibiotics alter gut 
bacteria and can result in altering hepatic drug metabolizing capacity, however, the 
effect of probiotic, prebiotic, and antibiotic use on the expression of hepatic drug 
metabolizing enzymes still remain virtually unknown. Therefore, it would be interesting 
to feed GF and CV mice probiotics, prebiotics, and antibiotics, and then quantify the 
expression of drug metabolizing enzymes in liver. To overcome the differences in drug 
metabolism between rodents and humans a similar study can be performed in humans, 
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to investigate how taking over-the-counter probiotics or prescription antibiotics can 
affect the pharmacokinetics and pharmacodynamics of other orally administered drugs. 
Another interesting study will be to quantify gene expression of important drug 
metabolizing enzymes at different post-natal time points during development in both GF 
and CV mice. This would illustrate the influence of gut bacteria in the regulation of drug 
metabolizing enzymes during development. Gut bacteria might normally regulate liver 
maturation by regulating the immune system; therefore, the ontogeny of important drug 
metabolizing enzymes must be altered in GF mice compared to CV mice.  
The above mentioned experiments are only just a few of the many exciting 
studies that will expand our understanding of the symbiotic relationship between the 
host and gut bacteria and how perturbations in gut bacteria can influence health and 
diseases. 
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